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Microneedles can act as an effective enhancer for transdermal drug delivery by painlessly 
breaching the skin surface and providing an alternative transport pathway. Increasing 
studies have been carried out on microneedles for transdermal drug delivery, most of the 
publications focus on fabrication technology of microneedles and general application of 
microneedles. However, there are still a number of issues that limit the widespread use of 
microneedles in pharmaceutical and cosmetic fields, including the exact mechanism of 
microneedles in facilitating the skin permeability of drug, reasonable design of 
microneedle product for effective drug delivery, and safety concerns over the use of 
microneedles.  The safety issues include the potential toxicity resulted from enhanced 
delivery of active ingredients and excipients, and the potential infection risk associated 
with a compromised stratum corneum. This thesis is focused on these issues that will 
influence the commercialization of microneedle products. 
A tripeptide copper complex (GHK-Cu) was used in this thesis to study the factors 
influencing microneedle-mediated transdermal drug delivery efficacy with the aim to 
explore the underlying mechanisms of enhanced delivery by microneedles. It was 
demonstrated that microneedle application force can influence the performance of skin 
permeation of copper peptide by affecting the penetration properties in skin. This finding 
is very important for the design of microneedles and the correct use of microneedles for 
effective skin permeation enhancement. Besides, it was found that human epidermis and 
rat skin may not be suitable models for in vitro skin permeation study when microneedles 
are used, although they are good models for conventional transdermal delivery.  
Microneedles showed a dramatic enhancement in the skin permeation of GHK-Cu, which 




beneficial effects. However, whether other copper compounds can be used together with 
microneedles for copper delivery and whether enhanced delivery of copper through skin 
can cause any toxicity to skin are unknown. Therefore, the skin toxicity potential of copper 
peptide (GHK-Cu) was compared with two other copper compounds, copper chloride and 
copper acetate by an in vitro skin irritation test with multiple biomarkers used. It was 
demonstrated that GHK-Cu has a low potential of inducing skin irritation response when 
compared to copper chloride and copper acetate. The proposed in vitro skin irritancy test 
approach may also be useful to assess the irritancy potential of other similar inorganic 
compounds or minerals through the skin.  
The use of microneedle in percutaneous drug delivery is also associated with the risk of 
infection because of the compromised SC. We managed to develop novel quaternary 
ammonium silane (QAS) antimicrobial copolymers which showed lower toxicity 
compared to the commercial QAS agent and the resulted coatings showed enhanced 
effectiveness and durability. Furthermore, microneedles with effective antimicrobial 
property was developed by coating with the synthesized copolymer, PDT-10% and good 
biocompatibility of the coated microneedles was demonstrated. The   antimicrobial 
microneedles can potentially minimize the infection associated with microneedle usage. 
Lastly, we fabricated an adhesive-free and solvent-free skin patch, namely dry patch, for 
the percutaneous delivery of lidocaine, to be applied together with microneedles. By 
comparing the percutaneous delivery of lidocaine and lidocaine HCl, it was found that the 
hydrophilic molecule, lidocaine HCl is the preferred molecule for a microneedle-assisted 
drug delivery system other than lidocaine.   The new patch system can achieve a similar 
effectiveness as the commercial patch yet with a faster onset, although 40 times less drug 
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Chapter 1 Background 
1.1. Transdermal drug delivery  
As the largest organ of the human body, skin provides a painless and compliant interface 
for systemic drug administration, which is referred to as transdermal drug delivery. 
Transdermal drug delivery has several advantages, including the bypassing of first-pass 
metabolism, avoidance of gastrointestinal side effects, possibility of extended therapy, ease 
of termination when needed, painless and friendly pediatric applications (1). Since the first 
transdermal patch was approved for use in 1979, there are 21 transdermal delivery systems 
approved by US Food and Drug Administration (FDA) (2). 
However, the skin itself by nature, is to protect the human body from environment. 
Therefore, the molecules that passively diffuse though skin are quite limited. As a general 
rule, only hydrophobic drugs with a molecular weight less than 500 Da are able to passively 
diffuse through the skin (1).  
1.2. Human skin structure and the barrier for cutaneous absorption 
 
Figure 1.1 (A) Skin layers: hypodermis, dermis (containing blood vessels (1), lymph 
vessels (2), nerve endings (3), sense receptors (4), hair follicles (5), sebaceous glands and 
sweat glands (6)) and epidermis. (B) Layers of the epidermis: basal layer, stratum spinosum, 
stratum granulosum and the stratum corneum. The cells found in this layer of skin are 
keratinocytes with different levels of differentiation, Langerhans cells (1) and melanocytes 




Human skin comprises three basic layers, epidermis, dermis and the subcutaneous fat 
(Figure 1.1A). The stratified, avascular epidermis consists of five layers, stratum corneum, 
stratum lucidum (found in thick skin), stratum granulosum, stratum spinosum and stratum 
basale (Figure 1.1B). The five layers of epidermis have different morphology and varying 
levels of keratinocyte differentiation. Stratum basale contains the mitotically active 
keratinocytes. The cells of this layer divide and migrate upwards towards the outer layers.  
Stratum corneum, also known as horny layer, the outermost layer of epidermis, is the final 
stage of differentiation. It is made up of 10 to 30 continuous thin layers of highly 
keratinized dead cells (corneocytes) surrounding by tightly packed intercellular lipid multi-
lamellae (4). The stratum corneum structure was described as ‘brick and mortar’ model, 
where the corneocytes represents the ‘bricks’ and the intercellular lipid bilayers represents 
the ‘mortar’ (5). The mechanically stiff structure presents a strong barrier to protect skin 
from infection, body water loss, chemicals and mechanical stress.  
On the other hand, due to the existence of the stratum corneum barrier, most cosmetic and 
pharmacological agents are unable to be absorbed by the skin. Thus the number of cosmetic 
and drug candidates that can be successfully delivered through skin route is limited (6).  
Drug absorption across skin can be subdivided into transappendageal pathway and 
transepidermal pathway. As sweat glands and follicles constitute only 0.1% of total skin 
area, drug absorption by the transappendageal pathway is limited (7). Transepidermal 
pathway can be further subcategorized into transcellular and intercellular routes. For 
transcellular routes, the drug molecules have to partition into hydrophilic corneocyte 
domain and diffuse across hydrophobic intercellular lipid lamellae, which is highly 
challenging for most molecules. Therefore, intercellular pathway is supposed to be the 




relatively small in surface area (8-10). As a general rule, only hydrophobic molecules with 
a molecular weight less than 500 Da are able to passively diffuse through the skin (1).  
1.3. Enhancement of skin permeation 
The highly impermeable nature of skin extensively limits cosmetics and drugs to be 
delivered via skin route. Hence, great efforts have been made to increase the permeability 
of the stratum corneum chemically or physically.  
Conventional strategy to increase skin permeation for drug absorption involves the use of 
chemical enhancers. Chemical enhancers act by enhancing drug solubility in formulation, 
increasing partition in stratum corneum, or disrupting the intercelullar stratum corneum 
(11). The chemicals identified to increase the skin permeability include alcohols, dimethyl 
sulfoxide, sulfactants, amines, amides, azones, fatty acids and terpenes (8). Ideally, 
chemical enhancers should be nontoxic, nonirritant and nonallergenic and the skin barriers 
function should recover immediately after their removal. Unfortunately, many of these 
chemical enhancers have skin irritation issue (1).  Meanwhile, this method is only 
applicable to the enhancement of small molecules and the amount of drug permeated 
though skin is limited (1).  
Physical enhancers thus are developed as alternatives to disrupt the stratum corneum for 
the delivery of large molecules. These include iontophoresis, ultrasound, electroporation, 
thermal ablation, and microneedles. They have different mechanisms to increase the skin 
permeability and are currently in various clinical trials and FDA approval process for 
transdermal delivery of macromolecules and vaccines, including insulin, parathyroid 
hormone and influenza vaccine (12). 
Iontophoresis acts by applying a small electric current to the skin (< 500 μA/cm2) for 




of lidocaine hydrochloride and epinepherine bitartrate for dermal analgesia, fentanyl for 
on-demand systemic delivery, sumatriptan for the treatment of migraine (2). Iontophoresis 
was reported not suitable for the transdermal transport of molecules larger than 7000 Da 
(13). However, with the combination of chemical enhancers, liposomes systems or 
microneedles, iontophoresis was able to deliver larger molecules, such as insulin and 
bovine serum albumin (14, 15). It was regarded as one drawback of iontophoresis that the 
current penetrates mostly via the skin appendages. Thus the current in the hair follicle may 
be high enough to cause damage although the overall current per unit area was low (3).  
Different from iontophoresis, electrophoresis utilizes a high voltage (≥ 100 V) for short 
duration (10 μs to 100 ms) thereby creating transient hydrophilic pores across skin. These 
pores allow the transport of a large range of molecules through skin, including small 
molecules, proteins and oligonucleotides (16). Although the electric field of 
electroporation is located at the stratum corneum, it may also affect the deeper tissues to 
cause pain (3). It was reported that only small region of skin would be affected, but more 
research should be done on the safety issue of the device. 
Sonophoresis applies ultrasound in a continuous or pulsed mode to the skin surface after a 
topical formulation was applied. High-frequency sonophoresis (f > 1 MHz, noncavitational 
ultrasound) has been used since 1950s for topical drug delivery (17). Skin permeability 
enhancement of noncavitational ultrasound was usually limited to small, lipophilic 
molecules.  Using more aggressive noncavitational ultrasound is limited since it will 
damage deeper tissue (1). Low-frequency sonophoresis (f < 100 kHz, cavitational 
ultrasound) was later found to be more effective in enhancing the transdermal drug delivery 
by disturbing the lipid packing in the stratum corneum via cavitation (17). Low-frequency 
sonophoresis was reported to be able to facilitate the transdermal delivery of hydrophilic 




oligonucleotides, even nanoparticles and liposomes (18). One problem associated with 
ultrasound is miniaturizing the complicated system for home use and high cost of 
fabrication. 
Thermal ablation applies localized heat for a short period of time to create micro-scale 
hydrophilic pores across the stratum corneum (19). The heat can be induced by various 
energy sources, such as radiofrequency (20), electrical heating elements (19) and lasers 
(21). In vivo study on animals demonstrated that human growth hormone and interferon 
alpha-2B can be delivered by skin with thermal ablation treatment (22, 23). The design of 
thermal ablation devices should precisely control the temperature (above 100 °C), duration 
(millisecond time scale or shorter), and localization of thermal energy applied to the skin, 
otherwise deeper skin tissue may get damaged. 
Although the above mentioned physical enhancers have shown great promise for 
transdermal delivery of hydrophilic and large molecules, all of them require electrical 
power with sophisticated fabrication, which may render a high set-up and maintenance cost. 
They are also relatively large although efforts have been made to reduce their size. 
Furthermore, special training may be required to use such devices. The search for 
inexpensive and efficient transdermal drug delivery with convenient and safe properties 
leads to the development of microneedles.  
1.4. Advantages of microneedles for drug delivery 
Microneedles, an array of micron scale needles, are thought to be the hybrid of convenient 
and safe transdermal patches and efficient hypodermic injections.  The idea of low-cost 
microneedles was first proposed in the 1970s (24), but microneedles were only made 
suitable for pharmaceutical application until the 1990s when microfabrication tools 




microneedles with various shapes, lengths and needle to needle spacing (26). They can be 
made long enough to breach the stratum corneum to increase the skin permeation, but short 
enough to avoid stimulating the nerves and blood vessels in the underlying dermis.  
The advantages of microneedles can be 
(1) Enhancement of the delivery of a large range of molecules, including hydrophilic drugs, 
peptides and proteins, to exert either topical effect or systemic effect (27-29); 
(2) Targeted vaccine delivery to antigen-presenting cells (e.g., Langerhans cells and 
dermal dendritic cells) in skin, and possible self-administration of vaccines (30); 
(3) Painless drug administration and increased patient compliance; 
(4) No fear of needles to the patient; 
(5) Avoidance of the risk of infection due to needle re-use with the use of dissolving 
microneedles; 
(6) Faster healing of skin than that with hypodermic needles (31, 32); 
(7) Avoidance of first-pass metabolism; 
(8) Ease of termination of treatment by removing the microneedle patch; 
(9) Dose reduction because of the enhanced drug delivery efficacy; 
(10) Choice of complex release patterns (bolus/sustained) (33). 
1.5. Materials of microneedles 
Microneedles have been fabricated with various materials, such as silicon, glass, metals 
(stainless steel, titanium) and all kinds of polymers (34). Silicon and glass used to be 
attractive options to fabricate microneedles since they are common materials in the 
microelectronics industry and have good adaptability to many fabrication procedures. 
However, silicon and glass are expensive and silicon is not a FDA approved material (35). 




relatively fragile (36). Compared with polymer microneedles, metallic microneedles are 
also less attractive, because of their high cost and the difficulties with mass production (37). 
Besides, silicon, glass and metals are non-biodegradable and thus safety issues arise when 
breakage in the skin happens. Polymeric microneedles overcome the limitations of silicon, 
glass and metal microneedles. They provide advantages like low cost, improved resistance 
to shear-induced breakage due to their viscoelastic property, and safety in case of 
accidental breakage in the skin tissue (37).  
Various biocompatible polymers have been used to produce microneedles. Natural 
polymers and sugars, such as thermoplastic starch (38, 39), carboxymethylcellulose (33), 
amylopectin (33), dextran (40), maltose (41, 42) and galactose (43) have been studied for 
microneedle fabrication. Microneedles made from carbohydrates provided rapid drug 
delivery due to their rapid dissolving nature in the skin.  Dextrin was used to fabricate 
microneedles without any special equipment (33). However, they have processing issues 
such as caramelization and difficulties in handling of molten sugar. Besides, sugar 
microneedles tend to be hygroscopic, which would be a problem for storage (43). A high 
Young’s modulus of the material is required to ensure sufficient mechanical strength of the 
microneedles fabricated (44).  
 A lot of studies demonstrated the fabrication of microneedles from synthetic polymers, 
such as polyvinyl acetate (45), carbomer (45), polyetherimide (46), polycarbonate (29), 
polyethylene glycol (47), polylactide-co-glycolic acid (48), polyvinylpyrrolidone (49), and 
poly(methylvinylether maleic anhydride) (50). Kochhar et al. reported a single-step 
photolithographical method to fabricate polyethylene glycol microneedles by exposing 
macromer poly(ethylene glycol) diacrylate solution to UV light through a patterned 
photomask for a few seconds. Drug can be premixed with the macromer solution and 




sustained release (47). Bovine serum albumin was also successfully incorporated into the 
microneedles without compromising the structures of the protein (51). A polycarbonate 
hollow microneedle array was integrated into a device with a drug reservoir and springs 
for self-application of drug. Animal studies demonstrated that the device can be used to 
effectively deliver small molecules and proteins (29). Dissolving microneedles loaded with 
insulin were prepared from poly(methylvinylether maleic anhydride) solution using laser-
engineered molds (50). Dissolving polyvinylpyrrolidone microneedles for influenza 
vaccination was fabricated by photopolymerization of the monomer N-vinylpyrrolidone 
solution mixed with the lyophilized vaccine in a microneedle mold. Fast dissolution of 
microneedles was observed when inserted into pig skin. In vivo study demonstrated that 
this microneedle vaccine patch achieved more efficient lung virus clearance and better 
immune responses than intramuscular vaccination (49). Needle-free vaccination can be 
useful in case of outbreak of a pandemic. It may also prevent the potential risk from 
hypodermic needles reuse in third world countries. To get these products commercialized, 
however, they must be efficient and cost-effective (52). 
1.6. Modes of drug delivery by microneedles 
Generally, there are four modes of transdermal drug delivery by microneedles dependent 





Figure 1.2 Methods of drug delivery to the skin using microneedles (MN). Adapted from 
(53). 
(1) Solid microneedles can be used as pretreatment of skin before application of topical 
formulations, which is also called “poke and patch” approach (54).  Once the 
microneedles were removed from the skin, a drug-loaded patch or a semi-solid topical 
formulation (e.g., cream, gel, lotion, or ointment) was applied to the treated area. Then 
the drug can diffuse into the skin through the formed micro-sized channels.  This two-
step administration approach is technically simple. We do not have to consider whether 
or not the fabrication process of microneedles will compromise the drug stability. 
Current available topical formulations may be directly used for this approach, so 
reformulation of the drug may not be needed (55). The first microneedle paper on drug 
delivery adopted this approach for in vitro delivery of a model molecule, calcein, and 
the skin permeability increased by up to four orders (25). This approach has been 
studied for sustained delivery of drugs. However, the dosing of drug delivery into skin 




(2) Solid microneedles can also be coated with drug-loaded water-soluble formulations. 
After insertion into skin, the coating can dissolve from the microneedles into the skin, 
and then the microneedles can be removed. This approach is referred as “coat and poke” 
(54). This approach is attractive for a rapid bolus delivery of drug into skin. The coating 
process can be conducted at ambient conditions and the solid state of coated drug is 
more suitable for long-term storage even at room temperature (56). A large range of 
compounds have been coated on microneedles, including molecules with small 
molecular weight, proteins, vaccines, DNA and microparticles (27, 56-58). For this 
approach, an efficient coating procedure and a suitable coating formulation are 
required (59). Since the limited available area of microneedles tips, the quantities of 
drugs that can be coated are low. Thick coating can increase the coating amount, but 
the sharpness of microneedles may get compromised, thus the microneedle penetration 
ability is affected (55). Therefore, this approach is more suitable for very potent drugs, 
such as vaccines (57, 58). 
(3) Dissolving microneedles are made of biodegradable or water-soluble polymers/sugars 
with drugs encapsulated inside. Microneedles get degraded/dissolved inside skin and 
the drugs get released (33). This approach is also called “poke and release”. Since the 
needles disappear eventually, no bio-hazardous waste is left after use (49).  The release 
rate of drug is dependent on the dissolving rate of the polymer. Sullivan et al. 
developed an influenza vaccine microneedle patch out of vinylpyrrolidone monomer, 
the microneedles dissolved within minutes (49). Lee et al. showed that bolus delivery 
was achieved by encapsulating drug inside microneedles only, while sustained release 
over hours to days was possible by incorporating drug in the backing of microneedles 
(33).  Polylactide-co-glycolide microneedles were shown to provide controlled release 




microneedles usually cannot be fully inserted into skin. So to ensure an accurate dose 
of drug delivered into skin, it is desirable to load drug in the tips of microneedles only. 
Two-layered dissolving microneedles were developed to encapsulate sumatriptan in 
the microneedles tips (60). Chu et al. located drug at the microneedle tips by 
introducing a bubble at the base of microneedles and prevented drug diffuse to the 
backing layer of microneedles (61).  Polymer particle-based micromolding was 
possible to locate compounds in different regions of the microneedles (62). However, 
microneedle fabrication process often involves the use of UV irradiation, elevated 
temperature or organic solvents, which could impair the stability of fragile compounds, 
such as proteins and DNA (33, 48, 61). Similar to coated microneedles, the amount of 
drug that can be encapsulated inside the microneedles is also limited. Besides, high 
loading of drug might compromise the strength of microneedles. 
      For certain polymeric microneedles with drug incorporated inside, the drug can be 
released from the microneedles after microneedles are inserted into skin. However, the 
microneedles do not completely dissolve over time (63). This is another scenario of 
“poke and release”. Hybrid microneedles have also adopted “poke and release” 
approach to delivery drug into skin, e.g., solid silicon microneedles with biodegradable 
tips (64) or stainless steel electrode pillar with water dissolvable tips (65). 
(4) Hollow microneedles can be used to deliver liquid formulations into skin through the 
needle bore actively or passively. This approach is also known as “poke and flow”. 
Similar to hypodermic injection, hollow microneedles can be used together with a 
driven force such as pressure, thus allow faster rates of delivery. This is an important 
advantage over solid microneedles (53, 55, 66). Hollow microneedles are commonly 
used with a syringe to inject liquid solutions into skin. A reservoir filled with drug 




injection (67, 68). Rates of delivery can be modulated by a syringe (68), pressurized 
gas (69), a syringe pump (70), a spring (29), and a micropump (71, 72). Furthermore, 
a lab-on-a-chip system can be integrated with hollow microneedles to deliver the drug 
into skin in a controlled way (73). Moreover, hollow microneedles require not only the 
control of microneedle insertion process but also the fluid infusion into skin (53). 
Experimental data and numerical simulations showed that although geometry of 
microneedle tips largely controlled pressure drop for fluid infusion through the 
microneedles, the pressure were much less than those required for injection into skin. 
It indicated that the primary resistance to fluid flow was associated with infusion into 
the skin and not through the microneedles (74).  It was reported that the fluid flow rate 
into skin was optimized by inserting partially retracting microneedles after insertion, 
infusing at high pressure, using microneedles with a beveled tip, and adding 
hyaluronidase to the infusion solution. Hyaluronidase was used to reduce resistance in 
the skin during microneedle insertion by rapidly breaking down hyaluronan within skin 
collagen fibers. Seven fold increase of flow rate was observed with addition of 
hyaluronidase (69).  
      Current existing injectable formulations can be used directly in hollow microneedles. 
However, this loses the advantage of solid microneedle delivery methods to deliver 
dry-state drug formulations without reconstitution to improve drug stability and the 
patient convenience of a patch-based delivery method (53). Besides, hollow 
microneedles have the risk of clogging at tip opening. The hollow nature impairs the 
strength of microneedles. Thus fabrication of microneedles from polymers is restricted 
by the mechanical weakness of polymers and the simplicity of the micromolding 




The comparison of different drug delivery modes by microneedles are further summarized 
in Table 1.1. Although there are different microneedle designs and drug delivery strategies 
developed, each of them has advantages as well as disadvantages. For a given application, 
it is necessary to find the best microneedle design and drug delivery approach from these 
options. Poke and patch approach is the simplest design for microneedle-assisted delivery, 
since microneedles only need to be designed for biomechanical function (53). Most of the 
currently approved microneedle products are drug-free microneedles for cosmetic and 
other purposes. They can be adapted for drug delivery purpose by using poke and patch 
approach, which will be the focus of my thesis.  







Poke and patch No or limited reformulation needed 
Technically simple 
No pump or encapsulation/coating 
process required 
Sustained release 
Combination with other delivery 
methods, such as iontophoresis  
 
Two-step administration step 
No precise dosing  
 
Coat and poke Needle strength is retained after 
coating 
No patch or pump required 
Precise dosing 
 
An efficient coating procedure 
needed 
Reformulation of drug needed 
Small dose 
Reduction of needle sharpness/ 
penetration ability  
 
Poke and release No patch or pump required 
Precise dosing 
No sharp waste  
 
Reformulation of drug needed 
Small dose 
Impaired needle strength 
 
Poke and flow Adjustable rate of drug delivery  
Delivery of high volumes 
Integration into lab-on-a-chip 
systems possible 
Precise dosing 
Risk of clogging 
Impaired needle strength 






1.7.    Current issues with the use of microneedles 
Since the microneedle-based drug delivery paper was first published in 1998, there has 
been an exponential increase of research in this area (53). Most of these papers focus on 
fabrication technology of microneedles and application of microneedles in drug and 
vaccine delivery. However, there are still a lot of unsettled issues.  
1.7.1.  Microneedle application method and skin models used to study the 
microneedle-assisted system  
To achieve painless application, microneedles were usually fabricated in a range of 50 µm 
to 1000 µm in length. Because of the elasticity of skin, the depth of microneedle penetration 
into skin is less than the needle length itself. Certain force or speed are needed for 
successful penetration (76). A number of studies have been done on the effect of 
microneedle geometries, force of insertion, velocity of insertion and density of 
microneedles arrays on drug delivery (77-80). Oh et al.  reported that microneedles with a 
longer length and more needles per array had a better enhancement in calcein delivery (77). 
However, Verbaan et al. found that increasing the number of microneedles per array did 
not result in a significant increase of drug transport (78), while Wu et al.  found that beyond 
a certain number of microneedles there was only little increase in flux, as the relative 
reduction in skin resistance for diffusing molecules after each additional microneedle 
piercing was decreased (79). In another study, Yan et al. observed that with a same force 
(44.5 N) applied on microneedle array, further increase of needle length beyond 600 µm 
did not show a significant increase in drug flux. In addition, lower needle density arrays 
were more effective in enhancing drug flux (80). This may be explained by another paper 
that there was an increase in percentage penetration with an increase in needle spacing, 
which indicated that the increase of needle numbers per array doesn’t necessarily increase 




Verbaan et al. reported that piercing was not successful for microneedles with a length of 
300 µm, while it was possible with microneedle lengths of 550 µm and longer with manual 
application (82). In a further study, it was found that with the use of an electrically driven 
applicator, the piercing was more effective than manual application. A higher velocity 
resulted in a higher transport rate (78).   
These studies were conducted to explore the effect of microneedle application methods, 
microneedle length and needle density on drug delivery because it was supposed that the 
inherent factors that would influence drug delivery were depth of penetration and numbers 
of penetration after microneedle treatment. However, the inherent factors, the depth of 
penetration and numbers of penetration were not quantified directly in these studies, which 
may partly explain the above contradicting results. Therefore, it is important to directly 
quantify the depth of penetration and numbers of penetration and relate with the 
performance of microneedle-mediated delivery system. For a given microneedle array, it 
is necessary to study the effects of application method and application force on drug 
transport, to ensure consistent delivery of drug. 
Besides, different kinds of skin models were used in the above in vitro studies, ranging 
from animal skins, human dermatomed skin and human epidermis (77-82). The skin model 
chosen may also affect the performance of a microneedle system.  For passive diffusion 
through skin, it was found that the thickness and components of the stratum corneum was 
important to compare the different skin models. For microneedle-assisted drug delivery, 
the stratum corneum is breached by microneedles. The permeation rate-limiting step may 
transfer from the stratum corneum to the viable layers. However, limited studies have been 




1.7.2.  Formulation of drugs to be delivered 
When comparing different approaches of microneedles, it was usually mentioned that one 
advantage for “poke and patch” approach is no or limited need of reformulation (55). 
However, the passages created by microneedles altered the permeation properties of skin, 
i.e., drug can now penetrate skin in a much faster mass transfer rate than normal diffusion 
through the intact skin. This fundamental difference may potentially change the principles 
of dosage form design, which traditionally is based on the understanding that drugs diffuse 
through the tortuous fissures inside stratum corneum. However, there are only limited 
studies to show the effect of formulation on drug delivery with microneedle assistance 
currently. The charge of a drug can affect its permeation through skin. Banks et al. 
evaluated the effect of drug ionization on skin permeation of naltrexone, and its active 
metabolite, naltrexol, through microneedle-treated and untreated guinea pig skin by 
comparing different pH values of aqueous formulation. Naltrexol in its poorly soluble 
unionized form (at pH 8.5) showed only limited flux enhancement after microneedle-
treatment. However, in the highly-soluble charged state (at pH 4.5), naltrexol not only 
permeated across untreated skin much faster, but also showed a greater flux improvement 
post microneedle-treatment (83). Besides, it was also reported that the effect of co-
solvents/excipients on the percutaneous transport rates through microneedle-treated skin in 
a fashion different from that of intact skin (84). Due to the low diffusional resistance of 
microneedle treated skin, the skin permeation rate-limiting step may shift from skin to drug 
delivery systems (84). Thus, even for “poke and press” approach, it is equally important to 
study the formulation (including drug format, pH, solvent, concentration, and excipient) to 




1.7.3. Safety issue related with microneedle application  
Microneedles may cause mild, transient skin irritation. The length of microneedles was 
found to be closely related with skin irritation.  Microneedles with 400 µm length induced 
greater erythema and blood flow than microneedles with 200 µm length (85). Similar mild 
erythema was also found with other solid microneedles. They usually disappear within 
hours (85, 86). These studies showed that microneedles generally are safe to use. However, 
one should keep in mind that when microneedles were associated with the formulation to 
be delivered, enhanced delivery of drug and excipients might also raise safety issues, for 
example, causing irritation to skin.  So for a given microneedle-mediated drug delivery 
system, it is important to evaluate whether the enhanced delivery of drugs/excipients would 
cause any toxicity to human body. 
Besides, it is also important to consider whether the pathway created by microneedles in 
the skin might be sites for infection. An in vitro study was conducted to assess the ability 
of microorganisms to traverse microneedle-induced holes. It was found that microneedle 
puncture resulted in significantly less microbial penetration than that induced by 
hypodermic needle puncture and that no microorganisms crossed the viable epidermis in 
microneedle-punctured skin (87). In another study, the risk of bacterial infection associated 
with microneedle treatment was found no greater than that with a hypodermic injection 
(88). Furthermore, studies in animals and humans generally demonstrated no infection 
associated with the microneedle use. However, these studies were conducted on healthy 
subjects and the microneedle application sites were usually cleansed before application of 
sterile microneedles. Therefore, the infection risk of microneedle application is unknown 
in immune-compromised patients (89). Besides, microorganisms were shown to adhere to 
microneedles after its application (87). Different from hypodermic injections, 




microneedles is quite possible and inappropriate reuse of microneedles will increase the 
risk of infection. 
1.8. Hypotheses 
From above review, it was found that there are still a number of issues that limit the 
widespread use of microneedles in pharmaceutical and cosmetic fields, although increasing 
studies have been carried out on microneedles for transdermal drug delivery in recent years. 
My thesis will target at these issues related with microneedle mediated drug delivery 
systems with 3MTM Microchannel Skin System (MSS) used as the model microneedles. 
3M MSS comprises a microneedle array and a reusable handle, which is illustrated in 
Figure 1.3. The plastic microneedle array is injection molded from liquid crystal 
polymers (LCP) and comprises of a rectangular grid of needles (13 by 27 per array, or 
351 needles) centered on an oval array. The microneedles have square pyramidal shape 
with a needle height of about 700 µm and a tip-to-tip needle spacing of 500µm. 
 
Figure 1.3 (A) 3M™ MSS microneedle array and the individual needles. (B) Illustration 
of microneedle application with an applicator. 
Here are the hypotheses for the studies in the thesis: 
 The efficacy and safety of MN mediated transdermal drug delivery systems can be 




 Antimicrobial property of microneedles can be achieved by an antimicrobial 
coating to reduce the potential risk of infection related with the use of microneedles. 
 An adhesive and solvent free lidocaine HCl patch with low drug loading can 
achieve effective and fast anesthetic effect with microneedle pretreatment. 
1.9. Specific aims and objectives 
The specific aims and objectives of the studies are outlined below to prove the hypotheses: 
1. To study the influence of microneedle application force on drug delivery efficacy by 
influencing the depth and numbers of passages created. 
2. To investigate the difference of various skin models used in in vitro skin permeation 
study. 
3. To study the skin irritancy potential of enhanced delivery of drug (copper peptide). 
4. To develop antimicrobial microneedles to reduce the infection risk related with the use 
of microneedles.  
5. To study the influence of formulation factors, such as drug format and dosage form on 
microneedle-mediated delivery. 
6. To fabricate an adhesive-free lidocaine patch, specifically for microneedle mediated 
drug delivery system. 
To address these specific aims and objectives, the thesis is presented in five parts as 
discussed below. For each part, an individual introduction part would be included to clarify 
the specific background and purpose of study.    
In Chapter 2, we investigated the transdermal delivery of a tripeptide complex, glycyl-L-
histidyl-L-lysyl copper complex (GHK-Cu, copper peptide) with the assistance of 
microneedles. GHK-Cu is a widely used cosmetic ingredient, but has the issues of limited 




influence of microneedle application force on the characteristics of transport pathway 
created and the performance of skin permeation of copper peptide. We also investigated 
the difference of skin models used in microneedle-assisted transdermal drug delivery. The 
three skin models, i.e., human dermatomed skin, human epidermis and rat skin are 
commonly used in conventional transdermal drug delivery. The work was intended to 
provide insight on which skin model is suitable for assessing a microneedle assisted 
delivery system. 
In Chapter 2, it was demonstrated that the microneedles can enhance the delivery of 
copper peptide and make the delivery of copper supplement possible by skin route. 
However, the enhanced delivery of copper may present issues of skin toxicity. Thus, 
Chapter 3, we further investigated the skin toxicity potential of copper peptide (GHK-Cu) 
and compared it with two other copper compounds, copper chloride (CuCl2) and copper 
acetate (Cu(OAc)2) using an in vitro skin irritation test by using multiple biomarkers. Based 
on the mechanism of skin irritation, we examined and proposed a paradigm to assess the 
skin irritation potential of copper compounds using cytotoxicity assay, gene and protein 
expression levels of cytokines and other newer biomarkers. To our knowledge, this is a 
first study evaluating the irritancy of different types of copper compounds at the cellular, 
genomic and proteomic levels using keratinocyte cell line. This approach may also be 
useful to assess the irritancy potential of other similar inorganic compounds or minerals 
through the skin, which is potentially a valuable tool in the cosmetological, dermatological 
and pharmaceutical fields. 
In Chapter 4, we fabricated novel quaternary ammonium silane (QAS) based 
antimicrobial copolymers with low toxicity which can form effective and durable coating. 
Subsequently in Chapter 5, one of the synthesized QAS copolymer, PDT-10%, was used 




the potential infection issue associated with microneedle usage. The biocompatibility of 
the coating was investigated as well. 
In Chapter 6, we hypothesized that microneedles would create an alternative pathway for 
drug permeation though skin and it should have a preference of drug molecules different 
from conventional passive percutaneous drug delivery. The percutaneous delivery of 
lidocaine and lidocaine hydrochloride (HCl) was compared with microneedle pretreatment. 
Furthermore, the drugs were fabricated into an adhesive and solvent free patch, named “dry 
patch” by spraying coating with limited excipients incorporated inside. The efficacy of the 
resulted dry patch together with microneedle pretreatment was investigated by both in vitro 






Chapter 2 Microneedle-mediated delivery of copper peptide 
through skin 
(Adapted from Pharmaceutical Research. 2015, 32(8):2678-2689) 
2.1.  Introduction  
Glycyl-L-histidyl-L-lysyl (GHK) is a naturally occurring carrier tripeptide with high 
affinity for copper ions (Figure 2.1). GHK was first isolated from human plasma by Dr L. 
Pickart because of its activity to prolong survival of normal liver cells (90). Subsequently, 
researchers found that GHK-Cu can stimulate the synthesis of extracellular matrix 
macromolecules, such as collagen and glycosaminoglycan (91-93). It can activate the 
production of metalloproteinases and anti-proteases that remove damaged proteins from 
the extracellular matrix macromolecules (94). GHK-Cu was also found to increase decrorin 
expression and decrease TGF-beta expression, which is beneficial for a scar-free healing 
(95, 96). The increased expression of p63 of keratinocytes by both GHK-Cu and GHK 
suggests that GHK and its copper complex can promote the survival of basal stem cells in 
skin (97, 98). These contribute to the wound-healing and skin remodeling effects of GHK-
Cu (91, 99-103). The biochemical action of GHK and GHK-Cu on skin cells were 
summarized in Table 1.1. Recent genomic studies revealed that GHK can directly 
modulate the expression of a large number of human genes and reverse gene expression to 
a healthier state, which may explain the diversity of its biological actions (104-106). 
Furthermore, in vivo studies showed that GHK-Cu can improve hair growth, skin 





Figure 2.1 Chemical structures of GHK peptide and its copper complex. 
Table 2.1 Biological effect of GHK-Cu on skin cells. 
Factor studied Cells Effective or 
tested 
concentration  




10-12 M to 10-8 
M 
Increased procollagen 
synthesis at mRNA level 
with a maximal 
stimulation at 10-9 M 
1. The stimulation 
is independent of 
any change in cell 
number and 
viability. 
2. The effect was 
reproduced by 
GHK alone but 
not by copper ions  
(91) 







10-12 M 1. Increased cell viability 
2. Increased type-1 
collagen expression at 
mRNA level but not at 
protein level 
3. Combination of red 
LED light and GHK-Cu 
treatment increased cell 
viability 12.5 fold, beta-











10-10 M to 10-8 
M  
1. Increased proMMP-2 
expression at both protein 
mRNA level with a 
maximal stimulation at 
10-9 M 
2. Increase TIMP-1 and 
TIMP-2 expression 
1. Cultured in 
Low-serum-
contained medium  




copper ions but 





1. Cell growth 






10-9 M 1. Enhanced cell growth 
of both cell types 
2. Increase the expression 
of bFGF and VEGF in 
irradiated human dermal 
fibroblasts 




10-9 M to 10-7 M  1.Increased expression of 
Glycosaminaoglycan 
with a maximal 
stimulation at 10-8 M 
2. Preferential 
accumulation of heparin 
sulphate in the cell layer 
and dermatan sulphate in 
the culture medium. 
  
Decorin Rat dermal 
fibroblasts 
10-9 M Increased decorin 
expression at both mRNA 
and protein level. 
1. Cultured in 
Low-serum-









level of TGF-beta, 
which is known to 
increase scarring. 
(95) 





10-9 M Decreased TGF-beta 
expression in both cells. 
1.Serum free 
culture 

















1µM in skin 
equivalent 
culture 
1. Stimulatory effect on 
keratinocyte growth 
2. Increased expression 
integrin alpha6, integrin 
beta1, PCNA and p63. 
P63 is putative 
stem cell marker 




survival of basal 
stem cells in the 
skin. 
(97) 












1µM GHK in 
skin equivalent 
culture 
1. Stimulatory effect on 
keratinocyte growth 
2. Increased expression 
integrin alpha6, integrin 










Minerals are essential for human health and mineral supplementation is recommended to 
complement dietary intake. Supplementation of minerals via oral route is the most common 
way. However, oral mineral absorption is affected by many factors including interactions 
with other dietary components in the gastrointestinal tract (109). Gastrointestinal side 
effects have also been reported with oral ingestion of some minerals, such as copper and 
iron. In addition, oral liquid forms of iron supplementation may cause teeth stains (110). 
To this end, transdermal delivery of minerals may be a useful alternative but remains 
largely unexplored. Copper as an essential trace element plays a critical role in diverse 
biological processes, such as haemoglobin synthesis and the stimulation of skin biomarkers 
including collagen and elastin (111). Copper also has an important role in the activation of 
key enzymes specific to tissue repair and in the cross-linking and maturation of collagen 
in healing wounds (110). Because of the gastrointestinal irritation that oral intake of copper 
can cause, transdermal delivery of copper can act as a good alternative, although skin 
absorption of charged ions is very low (112, 113). It was found that when GHK is coupled 
with copper, the peptide blocks the redox activity of copper, hence permitting the delivery 
of copper in a non-toxic form that can be subsequently utilized by the cells (97, 114).   
Although its biological actions start at picomole level, far higher dosages have been used 
in clinical trials, since the GHK-Cu uptake levels are very low through skin. On the other 
hand, if GHK-Cu is injected intradermally, GHK is rapidly cleared (95% clearance in 1 
min). The fragility and rapid breakdown of GHK is the major obstacle for clinical and 
cosmetic applications (115). In clinical trials involving GHK-Cu, large variations were 
observed and its efficacy towards the healing of indolent human wounds or skin ulcers 
were not found (99, 116, 117). To address the concerns, a variety of chemical modification 
to GHK has been carried out to produce breakdown-resistant copper complexes, e.g., 




1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid, but none were found better than GHK-
Cu (115).   
The low uptake of GHK-Cu by skin is a common problem associated with many other 
peptides and molecules. This is because skin itself in nature is to protect human body from 
environment. So the molecules that can be delivered though skin are quite limited. As a 
general rule, only hydrophobic molecules with a molecular weight less than 500 Da are 
able to passively diffuse through the skin (1). GHK-Cu with a log P of -4.5 can represent 
hydrophilic peptides that have difficulty in penetrating into skin (11). Because of the 
diverse biological effects of GHK-Cu, along with its potential as a source of copper 
supplementation, it is of interest to find out a method to enhance its skin absorption. 
As an alternative, we propose the use of microneedles, a minimally invasive but effective 
skin permeation enhancement method, to facilitate the effective and sustained delivery of 
GHK-Cu through skin. If an effective skin uptake of GHK-Cu is possible in a sustained 
manner with microneedle pretreatment, GHK-Cu is expected to better fulfil its biological 
effects. 
Microneedles with length in micron range can enhance skin permeability with no pain by 
breaching the stratum corneum layer of skin with self-administration (35). It has been 
shown that microneedles are associated with a lower risk of microbial infection than 
hypodermal needles (87). There are different methods of drug delivery to skin with 
microneedles, and microneedle pretreatment followed by a topical formulation have the 
advantages of possible extended release (53). Studies have shown that pretreatment of skin 
with microneedles can enhance delivery of topically applied formulations (28, 118), 




In this study, we investigate the effectiveness of a commercial microneedle product, 3M 
MSS, in enhancing the skin permeability of copper peptide, using both rat and human skin 
models. Since MSS is hand-applied by using an applicator, the effect of different thumb 
forces was studied.  In addition, we also carried out cell and animal testing to verify its 
safety.   
2.2. Materials and methods 
2.2.1.  Materials 
GHK-Cu and GHK were purchased from McBiotec, Nanjing, China. The ratio of GHK to 
Cu is 2:1 (manufacturer data). Copper standard solution (1 g/L), and trypan blue solution 
(0.4%) were purchased from Sigma-Aldrich, Singapore. Concentrated nitric acid (69% 
w/w) was purchased from VWR International S.A.S, Singapore. Rhodamine B was 
purchased from Alfa Aesar (Lancaster, UK). Phosphate buffered saline (PBS) (pH 7.4, 10×) 
was obtained from Vivantis, Malaysia. PDMS (Sylgard® 184 Silicone Elastomer Kit) was 
purchased from Dow Corning (Midlan, MI, USA). SolvableTM, an aqueous based tissue 
solubilizer, was purchased from PerkinElmer (Watham, MA, USA). Pierce® BCA protein 
assay kit was purchased from Thermo Scientific (Rockford, IL, USA). 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and dimethyl sulfoxide 
(DMSO) were purchased from MP Biomedicals, Singapore. Dulbecco’s modified Eagle’s 
medium (DMEM) and fetal bovine serum (FBS) were purchased from Life Technology, 
Singapore. Penicillin streptomycin solution was purchased from PAN-Biotech GmbH, 




2.2.2. Skin and microneedle application 
Human dermatomed skin (referred as human skin) was obtained from Science Care 
(Phoenix, AZ, USA). The skin tissues were excised from the thighs of Caucasian female 
cadaver, who died at the age of 92. Human epidermis was separated from the human 
dermatomed skin after the skin was immersed in 60°C water bath for 1 min. 
Besides human skin, rat skin was also chosen for the in vitro skin permeation and 
penetration study. Skin of rodents, including rats, is the most commonly used in vitro 
percutaneous permeation studies because of its availability (120).  Rat abdominal skins 
were obtained from National University of Singapore Comparative Medicine through the 
tissue sharing program. The hair on rat skin was removed by an electrical shaver followed 
by hair removal cream (VeetTM) application and removal after 2 min. Subcutaneous fat and 
connective tissues were also trimmed off (121).   
A  6 mm thick PDMS substrate was used to support the skin for microneedle application 
as reported (81).  The skin was spread over the PDMS substrate mounted on a Styrofoam 
board with epidermis side up. A microneedle array was then put on the skin sample. Four 
different forces were applied through an applicator at 4.5 N, 10.0 N, 13.3 N and 22.2 N for 
10 seconds, respectively, using a force gauge (HF-10, JISC, Japan). 
The use of animal skin was approved by the National University of Singapore Institutional 
Animal Care and Use Committee. The use of human skin was approved by the National 
University of Singapore Institutional Review Board.  
2.2.3. Depth of microneedle penetration measurement 
Microneedles were first primed with oxygen plasma in a plasma cleaner (Harrick Plasma, 




0.1% w/w rhodamine B solution and dried at 35 °C for 1 h. The rhodamine B coated arrays 
were then applied with a force of 4.5 N, 10.0 N, 13.3 N and 22.2 N for 10 seconds 
respectively on rat and human dermatomed skin samples. The depth of penetration was 
measured indirectly by recording the distance from the tip of the microneedles to the 
boundary where the rhodamine B coating was wiped off after skin insertion (28). To 
analyze the penetration depth of the microneedles, the microneedles were imaged using a 
stereoscopic microscope (Nikon SMZ25, Japan). The depth of penetration for each array 
was then determined by measuring 35 out of the total 351 microneedles per array. Three 
arrays were tested for each force. 
Confocal laser scanning microscopy was used to visualize the micro-conduits created in 
rat skin placed on a piece of glass slide. The scanning started from the stratum corneum 
side, through the z-axis of the microscope (A1R+si, Nikon, Japan) at 10× magnification. 
The excitation wavelength was 562 nm and fluorescence emission was at 570-620 nm for 
rhodamine B.  
2.2.4. Histological examination  
Histological examination of rat skin was carried out by cutting the microneedle treated skin 
samples into 10 μm sections using a Microcryostat (Leica, Germany). The histological 
sections were stained with hematoxylin and eosin and imaged using a microscope 
(Olympus, Japan).  
2.2.5. Field emission scanning electron microscopy (FE-SEM) 
After human dermatomed skin and human epidermis were treated with microneedles, the 
skins were immediately immersed in 2.5% glutaraldehyde (Sigma-Aldrich, Singapore) 




sample was attached to a SEM stub by a carbon tape (NEM tape, Nisshin EM. Co. Ltd.), 
and platinum sputter-coated using a JFC-1600 autofine coater (JeOL, Japan) at a current of 
10 mA for 80 s. The images of the skin were then taken using a JSM-6700F field emission 
scanning electron microscope (JEOL, Japan).  
2.2.6. Percentage of penetration measurement 
The percentage of penetration was tested using trypan blue coated microneedles. 
Microneedle arrays were first treated with oxygen plasma for 3 min, flood-coated with 70 
µl of trypan blue solution and then dried at 35 °C for 1 h. After application of a microneedle 
array with the specified force on skin, the skin was cleansed with water. Application sites 
were then imaged by using the stereoscopic microscope. The visible insertions were 
counted and the percentage of penetration (the number of stained dots divided by the total 
number of array microneedles) was calculated. At least 3 replicates were performed at each 
force. 
2.2.7. In vitro skin permeation study  
Vertical Franz diffusion cells with an effective exposed area of 1 cm2 were used. The 
pretreated skin samples were mounted onto Franz diffusion cells with epidermis facing up. 
The intact skin was used as control. The donor cell contained 2 ml of 5.8 mM (GHK)2Cu 
(the molar ratio of GHK to Cu in the raw material was 2 to 1) solution while the receptor 
cell contained 4.8 ml of 1× PBS. The cells were placed inside a chamber with temperature 
controlled at 32 °C (comparable to the physiological temperature of the skin surface). 
Magnetic stirrers in the receptor cells stirred at a speed of 100 rpm. The receptor solutions 
were withdrawn at pre-set time intervals and replaced with fresh ones. The receptor 
solutions were subjected to the measurement of copper permeated through the skin by 




performance liquid chromatography (HPLC). At completion, the skin surface was washed 
by rinsing the donor and receptor compartments with 1 ml water 3 times respectively. The 
skin was then removed from the diffusion cells, dried with Kimwipes and collected into 
Falcon tubes for the measurement of copper retained in skin by AAS (122). Three replicates 
were conducted for each group. 
2.2.8. AAS method  
Copper concentrations were determined by using an atomic absorption spectrometer 
(PinAAcle 900T, PerkinElmer) with acetylene flow rate of 2.5 L/min and compressed air 
flow rate of 10 L/min. The instrument was calibrated with Cu working standards (1.57 - 
62.95 µM) made from Cu stock standard solution (1 g/L) with 2% nitric acid as diluent. 
Diluted permeation samples collected from receptor solutions were then aspirated into the 
air/acetylene flame where Cu atoms absorb light of 324.75 nm. All readings of standards 
and samples were conducted with the instrument in the absorbance mode. To digest skin 
tissues prior to analysis, concentrated nitric acid was used as previous studies have shown 
that it quantitatively releases trace elements from biological tissues (123). Nitric acid of 
2.5 ml was added to each of the Falcon tubes containing skin samples and heated at 80 °C 
using a thermostatic water bath until complete digestion of the skin samples (123). After 
that, they were topped up to 10 ml using deionized water and filtered using 0.22 μm 
polytetrafluoroethylene membrane. The filtered solution was used for the measurement of 
copper retained in skin. 
2.2.9. HPLC method  
The amount of GHK permeated was determined by using Hitachi L2000 LaChrome Elite 
HPLC system with Agilent Bio SCX NP3 column (50 mm x 4.6 mm, 3 μm). The mobile 




M NaCl) with a gradient elution program with a mixture of solvents A and B as follows: 
0% B for 1 min, 1 – 100% B for 1 – 5 min, 100% B for 5- 8 min, 100 – 0% B for 8 – 8.1 
min, and 0% B for 8.1- 11 min. The flow rate was set at 0.5 ml/min. The injection volume 
was 20 μl for each sampling and ultraviolet detection was performed at a wavelength of 
218 nm. A calibration curve was conducted using GHK standard solution from 1.18 μM to 
587.58 μM.  
2.2.10. Skin total protein determination 
Skin samples were put into a 2 ml tube with 1.5 ml SolvableTM added. Then the tube was 
heated at 60 °C for 4 hours to allow the completely dissolution of skin. The total protein 
level of skin was determined by using a Pierce BCA protein assay kit after the skin 
digestion solution was diluted appropriately with water. 
2.2.11.  Cytotoxicity assay of GHK-Cu on skin cells 
The cytotoxicity of different concentrations of GHK-Cu against human adult low calcium 
high temperature (HaCaT) keratinocytes and human dermal fibroblasts (HDF) were studied 
by MTT assay in 6 replicates. Briefly, 5,000 cells in 200 μl culture medium (DMEM 
supplemented with 10% FBS and 1% penicillin-streptomycin solution) per well were 
seeded into 96-well plates and incubated for 24h. The culture medium was then removed. 
Subsequently, 180 μl fresh culture medium and 20 μl of GHK-Cu samples (0.058 - 58000 
µM (GHK)2Cu in PBS) were added per well and incubated for 24 , 48 and 72 hours, 
respectively. For control group, 180 μl fresh culture medium and 20 μl of PBS were added. 
At the respective analysis point, the medium was removed. The wells are washed with 200 
μl PBS and replenished with 200 μl fresh medium per well. Twenty μl MTT solution (5 
mg/ml in PBS) was added to each well, after which the plates were incubated for an 




in 150 μl DMSO. Absorbance was recorded at 595 nm with a microplate reader (Tecan, 
Switzerland). Wells containing DMSO alone were used as the blank. Percentage of cell 
viability was expressed as (Asample - ADMSO)/ (Acontrol - ADMSO) × 100%.  
2.2.12. In vivo irritation test on pigs 
Young adult swine (Yorkshire X), ranging from 10 to 40 kg were used for the study. The 
animals were first sedated with ketamine (10 mg/kg) and then anesthetized with isoflurane 
gas. Atropine was administered to reduce salivary, tracheobronchial, and pharyngeal 
secretions. The ham area of pigs was shaved with an electrical shaver followed by a 
disposable shaver. The microneedles were applied on the skin with a hand force of around 
20 N (estimated by using the force gauge) for 10 s. Then the skin was observed for irritation 
and imaged with time. In another testing, immediately after microneedle treatment, the 
application site was covered by gauze saturated with GHK-Cu solution, then fixed with 
plaster. After 8 hours, the gauze was removed and the skin was imaged. The studies were 
repeated on 3 to 4 pigs. The pigs were later recovered. The procedure for animal testing 
was approved by the National University of Singapore Institutional Animal Care and Use 
Committee.  
2.2.13. Statistical analysis 
All results were presented as mean ± standard deviation. Statistical analysis was performed 
by one-way analysis of variance (ANOVA) followed by Tukey post hoc test using IBM 





2.3.1.  Depth of microneedle penetration  
In Figure 2.2A, the yellow line indicated the distance from the tip of the microneedles to 
the boundary where the rhodamine B coating has been wiped off after skin insertion. The 
value of the distance was taken as depth of penetration of microneedles. Figure 2.2B 
showed the direct measurement of the depth of penetration using confocal laser scanning 
microscopy by measuring the depth of the microneedle fluorescence pattern inside the skin. 
The depth of penetration associated with an application force of 13.3 N on rat skin was 
measured to be 130 µm with direct measurement and 146 µm using indirect measurement. 
It was found that the results obtained from indirect depth of penetration measurement 
method had no difference from those obtained by direct measurement method (p > 0.05). 
Hence, the indirect method was used for this study for its convenience. Furthermore, 
Figure 2.2C further ascertained the presence of microscale passages created by 
microneedles inside the rat skin. Figure 2.2D showed that the depth of penetration of 
microneedles increased linearly with application force both on rat (r2 = 0.9977) and human 
(r2 = 0.9758) skin samples in the tested force range from 4.5 N to 22.2 N. At 22.2 N, the 





Figure 2.2 Depth of microneedle penetration measurement. (A) Indirect measurement of 
depth of penetration using rhodamine B-coated microneedles. The yellow line shows the 
depth of penetration. (B) Confocal image showing the fluorescent pattern of a single 
microchannel after microneedle application. (C) Histological section of rat skin stained 
with hematoxylin and eosin after microneedle application. The yellow arrow shows the 
breach of epidermis. (D) Depth of penetration against force of microneedle (MN) 
application. 
2.3.2. Percentage of penetration 
The percentage of microneedle penetration in rat skin was measured using trypan blue 
coated microneedles. Figure 2.3A and B shows the representative image of rat skin, human 
dermatomed skin after application of trypan blue-coated microneedles at 22.2 N, 
respectively. The blue dots that remained on the skin indicated the successful penetration 
of microneedles into skin. The number of the blue dots was used to calculate the percentage 




microneedle application resulted in a higher percentage of penetration. The increase in 
force of microneedle application on rat skin resulted in a sharper increase in the percentage 
of penetration as compared to that on human dermatomed skin. The highest force of 22.2 
N made the percentage of penetration to be almost 100% on rat skin and 30% on human 
dermatomed skin. 
 
Figure 2.3 Percentage of penetration. Representative images of 22.2 N MN application 
force on rat skin (A) and human dermatomed skin (B). (C) Percentage of penetration 
against force. 
2.3.3. In vitro skin permeation study 
To assess the enhancing effects of the microneedles for GHK-Cu to permeate through skin 
at different forces of application, we performed in vitro drug permeation study. Upon 
topical administration, the copper ions are subjected to dynamic ligand exchange inside 
skin (122). Therefore, quantitative assessment of skin penetration of GHK-Cu is 
challenging. Hence, we analyzed the permeation of copper and GHK separately by using 
AAS and HPLC. Figure 2.4A and B showed that the amounts of copper and peptide 
permeated through rat skin were significantly increased after microneedle pretreatment.  
Figure 2.4C and D showed that for non-treated human dermatomed skin, there was no 




which may be from the skin itself (data not shown). With the microneedle pretreatment, 
copper and peptide were detected in the receptor solution. However, substantial high 
amounts of copper and peptide were detected only when a high force (22.2 N) was used. 
 
Figure 2.4  In vitro skin permeation study. The cumulative amount of copper (A) and 
peptide (B) permeated through rat skin pretreated with varying application forces. The 
cumulative amounts of copper (C) and peptide (D) permeated through human dermatomed 
skin pretreated with varying application forces. 
Figure 2.5 showed that there was no significant difference in the amount of copper retained 
in skins after 9 hours’ permeation study among the microneedle pretreated skin and the 






Figure 2.5 Cumulative amount of copper retained in skin after 9 h permeation study. The 
‘Clean skin’ refers to the skin that was not used in permeation study. 
2.3.4. Cytotoxicity assay of GHK-Cu on cells 
Figure 2.6 showed that (GHK)2Cu was not toxic to either HaCaT keratinocytes or HDF 
cells in the range of 0.0058 – 5800 µM. Besides, GHK-Cu at 5800 µM showed certain 
stimulatory effect on HDF proliferation. Other research groups have also shown that GHK-





Figure 2.6 Cytotoxicity study. Viability of HaCaT keratinocytes (A) and HDF (B) after 
incubation with (GHK)2Cu for 24, 48 and 72 h. 
2.3.5. In vivo irritation test on pig skin 
For blank microneedles, minimal erythema was observed immediately after removal of 
microneedles. Mild erythema was observed at 5 minutes but almost not visible after 25 
minutes (Figure 2.7A). For GHK-Cu application immediately after microneedle 





Figure 2.7 Representative images of in vivo irritation test on pig skin. (A) The skin 
conditions after microneedle application. (B) The condition of microneedle pre-treated skin, 
followed by application of 5.8 mM copper peptide for 8 h. The black marker dot and the 
marked rectangle area indicated the microneedle treated area. 
2.3.6. Test on human epidermis 
Apart from full skin and human dermatomed skin, human epidermis was also tested. From 
the SEM images of microneedle treated skin in Figure 2.8, we observed more and larger 
holes in human epidermis other than human dermatomed skin with the same microneedle 
force used. The epidermis was penetrated through and the carbon tape on the stub was 





Figure 2.8 SEM images of skin after microneedle treatment with application force of 22.2 
N. The yellow arrows indicate the breach of the skin surface by the microneedles.  (A) 
Human dermatomed skin. (B) Human epidermis. 
Skin penetration test with trypan blue coated microneedles and in vitro permeation study 
were also conducted on human epidermis.  
As shown in Figure 2.9A and B, the increase in force of microneedle application on human 
epidermis resulted a sharper increase in the percentage of penetration as compared to 
human dermatomed skin. The percentage of penetration on human epidermis approached 
100% at forces of 13.3 N and 22.2 N. 
As shown in Figure 2.9C and D, the permeation behaviour of GHK-Cu across intact 
epidermis was quite similar with that across intact human dermatomed skin as shown in 
Figure 3C and 3D. It indicated that epidermis is the main barrier for GHK-Cu to be 




mild force of microneedle application (4.5 N), there is a sharp increase in the GHK-Cu 
permeating through the human epidermis. When the epidermis was treated with a higher 
force, 13.3 N and 22.2 N, leakage of the donor solution was observed during the permeation 
experiment preparation despite repeating the experiment for three to four times, which 
made it impossible to continue the permeation study. This phenomenon could be explained 
by the differences in the percentage of penetration between human dermatomed skin and 
human epidermis. A microneedle application force of 13.3 N and 22.2 N resulted in close 
to 100% penetration of microneedles on the epidermis, while the proportion of 
microneedles that penetrated the dermatomed skin were around 18% and 30% respectively. 
Furthermore, Figure 2.8 showed that large holes were observed in human epidermis than 
that in human dermatomed skin at the same microneedle application force and the 
epidermis were penetrated through at force of 22.2 N. Due to the presences of many holes 
created in the epidermis within a small area treated by the microneedles of high forces, 
coupled with the already thin epidermal layer, the treated epidermis was unable to contain 
the weight of the donor solution. The loss of structural integrity of the microneedle treated 
epidermis could have resulted in the leakage of the donor solution into the receptor 





Figure 2.9 Microneedle penetration and permeation test on human epidermis. (A) 
Representative images of 22.2 N MN application force on human epidermis. (B) 
Percentage of penetration against force of MN application on human epidermis. (C) and 
(D) were cumulative amount of copper and peptide permeated through human epidermis 
treated with varying application force of microneedles, respectively.   
2.3.7. The effect of different donor concentration on skin permeation 
Besides the of 5.8 mM (GHK)2Cu solution used in the donor compartment, a higher 
concentration of (GHK)2Cu solution, 29.0 mM was also tried in the donor compartment to 
differentiate the donor concentration effect. The data was shown in Figure 2.10. When test 
was done on intact human dermatomed skin, no permeation of GHK-Cu was observed even 
when donor GHK-Cu concentration was as high as 29.0 mM. With the pretreatment of 
microneedles on human dermatomed skin, significantly higher skin permeation of GHK-





Figure 2.10 In vitro permeation study of GHK-Cu solution with different concentrations 
on human skin.  (A) and (B) are cumulative amount of copper and peptide permeated 
respectively. 
2.3.8. The effect of complexation on GHK delivery 
The permeation study was conducted with 11.6 mM GHK solution in the donor 
compartment as well, with the result shown in Figure 2.11. GHK-Cu permeation through 
intact skin was not observed, while significantly high amount of GHK-Cu permeated the 
skin with microneedle pretreatment. On the other hand, microneedle pretreatment did not 
show much influence on the skin delivery of GHK. 
 
Figure 2.11 Cumulative permeated peptide through human dermatomed skin in in vitro 




2.4.  Discussion 
Microneedles can painlessly enhance the skin permeation of a wide range of therapeutic 
compounds which can barely penetrate human skin (53). It has been reported that the 
microneedle application force and velocity can influence its enhancing effect (77-80). In 
this study we evaluated the skin permeation of topical GHK-Cu in vitro using a 
microneedle array from 3M Company. The 3M MSS is designed for manual application 
with a plastic applicator. The thumb forces tested were: 4.5 N (low), 10 N (medium), 13.3 
N (medium) and 22.2 N (high).  
To study the depth of needle penetration, two approaches have been used. One is the direct 
measurement of the microchannels inside skin by confocal laser scanning microscopy and 
the other is the indirect measurement. In the indirect measurement, the depth of penetration 
was obtained by measuring the length of needle tip where rhodamine B dye was wiped off 
(28). But the coating rhodamine B onto the microneedles was complicated. To simplify the 
microneedle coating procedure, we treated the microneedles with oxygen plasma, which 
was found to be very effective for rhodamine B coating.  
The linear relationship between depth of penetration and microneedle application force 
indicates that these two factors are strongly correlated. However, we cannot assume that 
the linearity will be the same when the force is out of the range (< 4.5 N or > 22.2 N)(124).   
The force range would be from 13 to 63 mN/needle in our study if converted to force per 
needle. Some of these forces are even lower than the insertion forces of reported 
microneedles. For example, Park et al. reports measured microneedle insertion force of 37 
mN with a tip 20 µm in diameter (125). It indicated that our microneedle array has a high 




To study the percentage of penetration, trypan blue coated microneedles were used. Trypan 
blue is known to specifically stain the sites of  the stratum corneum perforation (47). A 
common procedure is to treat the skin first with microneedles, and then transfer trypan blue 
solution on the treated area for targeted staining (47, 78). However, we found that wrinkles 
and hair follicles can also be easily stained. Besides, trypan blue solution has limited 
contact with skin surfaces to ensure staining of all the microchannels because of the 
hydrophobic nature of skin surfaces. To solve this problem, we coated trypan blue directly 
onto the microneedles and then conducted the penetration test on skin. The false staining 
on the skin surface was then wiped off with water. With the new method, we can easily get 
clear staining images indicating the successful penetration of microneedles.  
The results showed that with a higher force, the percentage of penetration increased. 
However, the effects are different on rat and human skins. Rat skin was much easier to be 
stained than human dermatomed skin. Trypan blue stains damaged cells selectively 
because the damaged cell membranes allow trypan blue to enter and stain the nuclei and 
cytoplasm (126). Since the stratum corneum is made up of layers of highly keratinized 
cells thus it will not be stained by trypan blue. Trypan blue can stain the epidermis at the 
sites of the stratum corneum perforation (81). Although rat full skin and human 
dermatomed skin samples had the similar thickness, around 500 µm, rat skin has a much 
thinner layer of epidermis (~15 µm, Figure 2.2C) than human skin (~200 µm). After the 
stratum corneum of rat skin is penetrated by microneedles, the viable epidermis below may 
be easily stained. On the other hand, the human skin has a more complicated structure. The 
layer below the stratum corneum is the stratum granulosum. Since the stratum granulosum 
is made up of partially keratinized cells without nuclei, it is more difficult to stain (127). 
In general, microneedle pretreatment can increase skin delivery of GHK-Cu, although the 




observed for non-treated rat skin, but almost none for intact human dermatomed skin. With 
microneedle pretreatment, the permeated amount of copper and peptide increased 
significantly than those through non-treated rat skin (Figure 2.4A and B). For human skin, 
microneedle pretreatment made permeated copper and peptide detectable. But substantial 
increase in the skin permeation was only observed at 22.2 N (Figure 2.4C and D).  
We noticed that the depth of penetration was proportional to application forces in both rat 
skin and human dermatomed skin models. For the rat skin, however, the microneedles can 
easily penetrate the entire epidermis at all the forces, as the thickness of epidermis of rat 
skin is ~15 µm (Figure 2.2C). Epidermis, especially, its outermost layer, i.e., the stratum 
corneum, is the main barrier. Thus, the permeation of copper peptide through rat skin was 
independent of depth of penetration in rat skin model, similar to another finding (81). 
Bachhav et al. also found the transport of lidocaine was independent of the depth of the 
microchannels created by laser after removal of the stratum corneum (21).  
In the case of human dermatomed skin model, when microneedle application forces were 
less than or equals to 13.3 N, increase in skin permeation was observed because the stratum 
corneum was penetrated, while the distinct increase in the skin permeation at 22.2 N may 
mainly be due to the penetration of whole epidermis layer (the epidermis layer of the human 
skin is ~200 µm). It indicated that viable epidermis layers are also significant permeation 
barriers (128).   
Apart from the two types of skin models (rat full skin and human dermatomed skin), we 
also tested human epidermis. Human epidermis has been widely used in in vitro skin 
permeation experiment to study the conventional transdermal drug delivery (129). Human 
epidermis has also been used to study microneedle assisted transdermal drug delivery (36, 




showed a much higher percentage of penetration with microneedles as compared to human 
dermatomed skin (Figure 2.8 and Figure 2.9). It may be because the thick dermis in the 
dermatomed skin could provide cushion effect and have absorbed some of the force applied 
onto the epidermal layer. Furthermore, a sharp increase in skin permeation of copper 
peptide was observed even with a mild microneedle application force on human epidermis 
(Figure 2.9). As such rat skin and human epidermis may have their limitations as models 
to study the physical enhancement of skin by using microneedles.  
 Furthermore, higher skin permeation of GHK-Cu can be obtained with the use of a higher 
concentration of GHK-Cu solution with microneedle treatment. However, no permeation 
of GHK-Cu was observed through intact human dermatomed skin even when the GHK-Cu 
concentration increased (Figure 2.10). It suggested that increasing GHK-Cu concentration 
alone in topical formulations might not be a good choice to improve the effect of the GHK-
Cu creams/gels. 
The ratio of copper to peptide permeated though rat skin was around 1:1, while when 
human skin models were used, the ratio was much higher. It may be partly due to the fact 
that more copper was retained in rat skin than in human skin. Moreover, GHK-Cu complex 
can permeate at faster rate than GHK alone (Figure 2.11Error! Reference source not 
found.), which suggested a potentially useful approach to deliver minerals through skin.  
Although it was found that application force was correlated with copper permeation 
through skin, no correlation was found between application force and copper retention 
inside skin. Partitioning of copper can be influenced by complexation with proteins in the 
skin (130). In this case, the skin proteins were probably saturated with copper at the end of 
the permeation study, thus no difference of copper was found inside the skin samples.  On 




the difference of protein content in the two types of skin. The weight of skin was around 
0.40 g and 0.10 g while the protein content was around 36 mg and 10 mg for one piece of 
rat skin and human dermatomed skin used in permeation study, respectively. The retained 
peptide in skin was not studied in this in vitro model since GHK peptide would degrade 
rapidly because of the existence of enzymes in vivo (131).  
Besides its efficacy, the skin irritancy potential of the microneedle array was also tested, 
using MTT assay to monitor the metabolic activity of keratinocytes and fibroblasts (132). 
The cytotoxicity assay showed that GHK-Cu was not toxic to HaCaT keratinocytes and 
human dermal fibroblasts in the range of 0.0058 – 5800 µM (Figure 2.6). From the in vitro 
permeation study, the highest amount of copper retained in skin was around 600 nanomoles 
(Figure 2.6). The weight of skin was ~0.4 g. So the retained copper can reach a 
concentration of ~150 µM by calculation, which is less than 5800 µM. Thus it is not 
expected to cause any skin side effects. Furthermore, irritation test on pig skin confirmed 
that the skin recovered quickly after microneedle application and the combination of 
microneedles and topical GHK-Cu formulation did not cause any skin irritation. The skin 
of the domestic pig is widely accepted as a suitable model for human skin for 
dermatological research and for percutaneous permeation studies because pig skin is 
usually considered as the closest in structure to human skin among different animal species 
(133). Pigs have also been used in the studies of microneedle assisted topical drug delivery 
(27, 28). Nevertheless, it is still necessary to further confirm the safety of microneedle 
assisted GHK-Cu application on human subjects.  
The recommended intake of copper for healthy adults is 0.9 and 1.3mg/day by American 
Food and Nutrition Board and World Health Organization, respectively (134, 135). In our 
study, about 705 nanomoles/cm2 of copper can permeate through human skin with the 




calculated from the permeation curve (Figure 2.4C). So about 721 nanomoles/cm2 of 
copper was expected to permeate through the skin in the next 15 hours. Altogether there 
would be about 1426 nanomoles/cm2 (which is about 0.091 mg/ cm2) of copper permeating 
through human skin in 24 hours with the assistance of microneedles. So a patch size of 9 
to 15 cm2 may be designed to meet the daily intake requirement of copper. 
2.5. Conclusion 
The application force was found to affect the percutaneous delivery efficiency of copper 
peptide by influencing the depth and percentage of microneedle penetration through skin.  
The skin permeation of copper peptide can be enhanced by microneedle pretreatment at a 
high thumb force with minimal skin disturbance. In 9 hours, 134 ± 12 nanomoles of peptide 
and 705 ± 84 nanomoles of copper can permeate though the pretreated human skin. It 
indicates that microneedles may be useful to deliver similar peptides or minerals through 
skin. Besides, human epidermis and rat skin may not be suitable models for in vitro skin 




Chapter 3 Selected biomarkers revealed potential skin toxicity 
caused by certain copper compounds 
3.1. Introduction 
Copper is an essential trace element critical for normal human metabolism and copper 
deficiency can occur with insufficient copper intake. However, excess copper intake may 
also cause toxicity to human. Copper and its alloys are present in numerous articles of 
everyday use, such as coinage, tools, jewelry, and dental materials, thus it comes in regular, 
sometimes extended and intimate contact with skin. For medical applications, copper 
intrauterine devices (IUD) are a type of long-acting reversible contraception because 
copper (II) ions released from the devices are deleterious to sperm cells (136). Direct and 
prolonged contact of copper with skin/mucosa may result in electrochemical reactions that 
release copper ions, which become diffusible through skin (130). Copper in its metallic 
state has no effect on the skin and it becomes a potential irritant or allergen only when it is 
corroded and thus become soluble through the action of exudates encountered on the skin 
surface, or in a relatively corrosive physiological environment such as the oral cavity or 
the uterus (137). 
Copper compounds have been used as paint pigments, as wood preservative and pesticides 
historically (138). Copper complex and compounds are also active ingredients/excipients 
in cosmetic and pharmaceutical industries, e.g., copper peptide for skin regeneration 
purpose, cupric aspirinate and cupric salicylate for rheumatoid arthritis treatment, copper 
conjugated dendrimer with antitumoral activity, and copper liposome for an enhanced 
stability of doxorubicin (139-143). Copper can also act as a delivery vehicle, where it is 
used in photothermal nanoparticles. These copper nanoparticles-mediated drug delivery 




transdermal drug delivery (144). With the developments of novel skin permeation 
enhancement methods such as microneedles and laser, copper compounds can be 
potentially used on skin for cosmeceutical or medicinal purposes (35, 139, 145).  Efficacy 
studies and safety studies are equally important for a successful development of a drug 
delivery system. However, many current studies are mainly focused on improving the 
pharmacodynamics and pharmacokinetics properties of copper, data on dermal toxicity by 
copper and its compounds is limited and their toxicity potential has not been well 
established.  
Furthermore, along with wide exposure of copper on the skin or mucosa, cases of contact 
dermatitis have been reported, although not frequent. A woman had a 5-year history of 
painful lichenoid lesions on the left mucosa and the left side of the tongue adjacent to a 
dental metal prosthesis containing copper. The symptoms relieved almost immediately and 
the lichen disappeared after the prosthsis had been changed to one without copper. 
Dermatitis and eczematous rash was reported with people with IUD. Hand eczema was 
reported with cashiers and other professionals handing coins which may be caused or 
aggravated by the release of metal including copper (137). Irritant effects have been 
frequently found from occupational exposures to copper-based pesticides, including 
allergic reactions, itching, and eczema (146). 
Considering the wide contact of coppers and its compounds in our daily life, data on dermal 
irritation by copper and its compounds is scant and the role of copper as an 
irritant/sensitizer remains controversial (137). A recent review paper on copper 
hypersensitivity concluded that copper is a weak sensitizer as compared with other metal 
compounds (147).  However, with the prevalence of skin permeation enhancement methods 




compounds may pose a higher risk on the disrupted skin, which necessitate thorough skin 
toxicity testing of the copper and its compounds.  
Animal tests for acute skin irritation assessment usually follows Draize rabbit test while 
the well accepted assays for skin sensitization include local lymph node assay (LLNA) and 
guinea pig maximisation test (GPMT). However, there is indication that the LLNA is 
deficient in detecting metals and organometallic compounds (148). Furthermore, because 
of questionable significance of animal data and ethical opposition to animal test, efforts 
have been made to find alternative testing methods to identify the skin toxicity chemicals 
(149-151). Most considerations of non-animal alternatives for skin irritation/sensitization 
tend to examine a single aspect of the process of induction (e.g. chemical reactivity, 
epidermal bioavailability, dendritic cell responses). However, experts in the area generally 
conclude that it will require a combination of data from multiple endpoints to truly 
discriminate and classify sensitizing and/or irritant substances in vitro. Besides, direct 
peptide reactivity assay (DPRA) is a kind of chemical reactivity assay recommended by  
the European Center for the Validation of Alternative Methods (ECVAM) for skin 
sensitization testing. However, DPRA is not suitable for metal compounds, because they 
may form bonds with nucleophilic residues in histidine (152). 
In Chapter 2, we demonstrated that the use of microneedle pretreatment can enhance the 
delivery of copper peptide and the safety of the combination was demonstrated by MTT 
cytotoxicity assay and in vivo pig study. In this chapter, we further investigate the safety 
of the skin toxicity potential of copper peptide (GHK-Cu) as well as two other copper 
compounds, copper chloride (CuCl2) and copper acetate (Cu(OAc)2) using an in vitro skin 
irritation test by using multiple biomarkers. Based on the mechanism of skin irritation, we 
examined and proposed a paradigm to assess the skin irritation potential of copper 




other newer biomarkers. To our knowledge, this is the first study evaluating the irritancy 
of different types of copper compounds at the cellular, genomic and proteomic levels using 
keratinocyte cell line. This approach may also be useful to assess the irritancy potential of 
other inorganic compounds or minerals through the skin, which is a critical tool in the 
cosmetological, dermatological and pharmaceutical applications.  
3.2.  Materials and methods 
3.2.1. Materials 
GHK and GHK-Cu were purchased from McBiotec (Nanjing, China). The ratio of GHK to 
Cu is 2:1 according to manufacturer data. Copper (II) chloride (99%) and copper (II) 
acetate monohydrate (≥ 98%) were purchased from Sigma-Aldrich (St. Louis, USA). 
Random primers and SYBR safe DNA gel stain were supplied by Invitrogen, Life 
Technologies (USA). RNeasy Mini Kit and QuantiFast SYBR Green PCR kit were 
purchased from Qiagen (Germany). Random primers and avian myeloblastosis virus 
reverse transcriptase were purchased from Promega (Madison, Wisconsin, USA). Human 
interleukin 1 alpha and interleukin 8 enzyme-linked immunosorbent assay (ELISA) kits 
were purchased from Biolegend (San Diego, CA, USA). Human Fos-related antigen 1 
(FOSL1) and Heat shock 70kDa protein 1A (HSPA1A) ELISA kits were purchased prom 
MyBioSource (San Diego, CA, USA). Reagents used for cytotoxicity assay was the same 
with that used in Chapter 2. 
3.2.2. Cytotoxicity assay  
The cytotoxicity of different concentrations of GHK, GHK-Cu, Cu(OAc)2 and CuCl2 
against HaCaT keratinocytes were studied by MTT assay in 6 replicates. Cells were seeded 




with 10% FBS and 1% penicillin/streptomycin solution) into 96-well flat-bottomed 
microtiter plates (Costar, Corning, USA) and incubated at 37 °C in humidified 5% CO2 
using AutoFlow NU-5510 Direct Heat CO2 Incubator (NuAire, USA) for 24 hours before 
treatment. The culture medium was then removed after 24 hours of incubation. 
Subsequently, 180 μl fresh culture medium and 20 μl of samples (0.058 - 58000 µM in 
sterile water) were added per well and incubated for 24, 48 and 72 hours. For control group, 
180 μl fresh culture medium and 20 μl of sterile water were added. At the respective 
analysis point, the medium was removed, washed with 200 μl PBS and replenished with 
200 μl fresh medium per well. Twenty μl of filtered MTT solution (5 mg/ml in PBS) was 
added to each well, after which the plates were incubated for an additional 4 h. The 
supernatant was then removed and resultant formazan crystals were solubilized in 150 μl 
DMSO. Absorbance was recorded at 595 nm with a microplate reader (Tecan, Switzerland). 
Wells containing DMSO alone were used as blank. Percentage of cell viability was 
expressed as (ASample - ADMSO) / (AControl - ADMSO) × 100 %. 
3.2.3.  In vitro skin irritation test  
HaCaT keratinocytes were cultured in DMEM containing 10% FBS and 1% 
penicillin/streptomycin and were maintained under 37 °C with humidified 5 % CO2. When 
the cells reached approximately 80% confluency, cells were harvested with trypsin and 
seeded at a density of 2.9 × 105 cells per well in 2.5 ml of culture medium into 6 well flat-
bottomed plates (Costar, Corning, USA) and incubated for 24 hr.  
GHK, GHK-Cu, CuCl2 and Cu(OAc)2 were used at a final concentration of 58 μM and 580 
μM. Sterile water was used as a control. All the chemicals were diluted with sterile water 




Then, 250 μl sample solution (580 and 5800 μM in sterile water) and 2.25 ml of culture 
medium were added into each well in triplicates. For control group, 250 μl sterile water 
and 2.25 ml culture medium were added. Cells were subjected to treatment in incubator for 
24 hours. Following treatment, the culture medium was recovered and used for protein 
quantification using ELISA. The cells in the appropriately labelled wells were used 
subsequently for messenger ribonucleic acid (mRNA) extraction.  
3.2.4. mRNA extraction  
mRNA was extracted from cells using the RNeasy Mini Kit in accordance with the 
manufacturer’s instructions. The concentration of mRNA were determined using 
NanoDrop 1000 Spectrophotometer (Thermo Scientific, USA). Reverse transcription of 
total mRNA were performed at 1 μg of total mRNA in 25 μl final volume using random 
primers and avian myeloblastosis virus reverse transcriptase. The concentration of 
complementary deoxyribonucleic acid (cDNA) after reverse transcription were also 
determined using NanoDrop Spectrophotometer.  
3.2.5. Quantitative real-time polymerase chain reaction (PCR) 
Quantitative real-time PCR reaction was performed using Rotor-Gene Q real time PCR 
cycler (Qiagen, Germany). Primers (Integrated DNA technologies, Singapore) used for 
PCR reactions were listed Table 3.1. Primers sequence for beta actin (ACTB), interleukin 
1 alpha (IL-1α), FOS-like antigen 1 (FOSL1), cofilin 1 (CFL1), bone morphogenetic 
protein 2 (BMP2) and heat shock protein 70 kDa 1A (HSPA1) were synthesized as 
previously described (153-155). While primer sequence for interleukin 8 (IL8), heat shock 
protein 27 (HSP27) and superoxide dismutase 1 (SOD1) were designed using Primer3 
(http://frodo.wi.mit.edu/) and Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-




seconds and 60 °C for 60 seconds, followed by gel electrophoresis on a 3% agarose gel 
stained with SYBR safe DNA gel stain.  
Table 3.1 DNA sequence of primer pairs used for quantitative real time PCR. 
 
A beta actin primer was also included as an internal loading control. Each reaction mixture 
was prepared using 10 μl QuantiFast SYBR Green PCR master mix, 4 μl of cDNA template 
with 1 μM of each primer in a total reaction volume of 20 μl. The PCR was run for 40 
cycles and the thermal cycling conditions were as follows: initial heat activation at 95 °C 
for 10 minutes; denaturation for 10 seconds at 95 °C; combined primer annealing and 
extension for 60 seconds at 60 °C. The fluorescence signal was measured at the end of each 
extension step. After the amplification, a melting peak analysis with a temperature gradient 
from 72 °C to 95 °C was performed. Fluorescence emission readings were analyzed using 
Rotor-Gene Q software (Qiagen, Germany). The data were presented as the fold increase 
Gene 
symbol 






(5’ to 3’) 
Reverse Primer 
(5’ to 3’) 
IL1A Interleukin 1 
alpha 
NM_000575 89 ggttgagtttaagccaatcca tgctgacctaggcttgatga 
FOSL1 FOS-like 
antigen 1 
NM_005438 75 aaccggaggaaggaactgac ctgcagcccagatttctcat  
HSPA1A Heat shock 
70kDa protein 
1A 




NM_001206 189 ggtggaatgactggattg gcatcgagatagcactg  
CFL1 Cofilin 1 NM_005507 285 tcttctgcctgagtgaggac tgatccctgtcagcttcttc 
IL8 Interleukin 8 NM_000584 139 tctggcaaccctagtctgcta agtgcttccacatgtcctcac 
HSP27 Heat shock 
protein 27  
AB020027 153 ctgcaaaatccgatgagactg caggtggttgctttgaacttt 
SOD1 Superoxide 
dismutase 1 
NM_000454 166 tcaatttcgagcagaaggaaa ccaccgtgttttctggataga 





of the target gene expression, normalized to the housekeeping gene beta-actin, compared 
to unstimulated conditions.  
3.2.6. ELISA 
Following treatment, conditioned medium was recovered and used to determine 
concentration of IL-1α, IL8, HSPA1A and FOSL1. The concentration of IL-1α and IL-8 
were measured quantitatively using ELISA kits in accordance with the manufacturer’s 
instructions. Absorbance was recorded at 450 nm using a microplate reader (Tecan, 
Switzerland). The unknown analyte concentrations in the samples were determined using 
a standard curve. The concentration range of standard curve for IL-1α was 3.9 – 250 pg/ml, 
for IL-8 15.6 – 1000 pg/ml, for FOSL1 31.2 to 1000 pg/ml and for HSPA1A 1.56 – 100 
ng/ml. Results were presented as pictogram or nanogram of mediator released per milliliter 
of conditioned medium.  
3.2.7. Statistical analysis 
Results were expressed as means ± standard deviation of at least three independent 
experiments. Statistical analysis was performed by one-way ANOVA followed by Tukey’s 
post hoc test using Minitab 16. The difference was considered to be statistically significant 
at p-value < 0.05.  
3.3. Results 
3.3.1. pH determination in water and culture medium  
GHK, GHK-Cu, Cu(OAc)2 and CuCl2 samples were prepared and diluted in sterile water 
and culture medium (DMEM supplemented with 10% FBS and 1% penicillin/streptomycin) 




recorded using the S220 SevenCompactTM pH/Ion meter (Mettler Toledo, Switzerland). 
The result was shown in Table 3.2. 
Table 3.2 pH of tested compounds dissolved in water and culture medium respectively. 
Concentration / Solvent 5800 μM  
Water 
5800 μM  
Culture medium 
580 μM  
Water 
580 μM  
Culture medium  
GHK 7.95 7.60 7.92  7.49 
GHK-Cu 6.74  7.23 6.41 7.35 
CuCl2  4.69 6.91 5.09 7.21 
Cu(OAc)2   5.87 6.92 5.56 7.37 
 
3.3.2. Cytotoxicity assay in HaCaT cells 
Cell viability tests were performed using HaCaT keratinocytes cells with treatment of GHK, 
GHK-Cu, CuCl2 and Cu(OAc)2 for 24, 48 and 72 h. After treatment with concentrations 
ranging from 0.0058 µM to 5800 µM, cell toxicity was not observed for both GHK (Figure 
3.1A) and GHK-Cu (Figure 3.1B). On the other hand, the toxic effect of CuCl2 and 
Cu(OAc)2 on HaCaT cells were concentration- and time- dependent. After 24 h treatment 
with 580 μM CuCl2 (Figure 3.1C) and Cu(OAc)2 (Figure 3.1D), there were statistical 
difference in cell viability as compared with control but high cell viability was still 
observed with more than 75 % viable cells. However, it was observed that cell viability 
decreased subsequently after 48 h and 72 h with treatment of CuCl2 and Cu(OAc)2. The 
cell viability was 13.7% and 38.2% for CuCl2 and Cu(OAc)2 groups at 48 h respectively 
and almost all the cells were dead for the two groups by 72 h. While at the highest 
concentration of 5800 µM, both CuCl2, and Cu(OAc)2 were found to be very cytotoxic to 





Figure 3.1 Cytotoxicity assay. Relative cell viability of HaCaT keratinocytes after 





3.3.3. Quantitative real-time PCR analysis 
Real-time PCR was then performed to determine the expression of 8 genes, which were 
involved in skin irritation and inflammation. These genes were previously found to be 
upregulated in the presence of irritants (153, 156). The fold changes in relative gene 
expression of treatment cells compared to sterile water treated control cultures were 
determined following 24 h of treatment. The changes in relative gene expression were 
calculated as the normalized ratio in treatment cells compared to that in control (sterile 
water).  Fold change in treated cells are presented as mean ± standard deviation.  ANOVA 
was performed between the control and treatment groups for each gene followed by 
Tukey’s post hoc test. * p < 0.05, is considered to be statistically significant. The result is 
shown in Table 3.3. 
From Table 3.3., it was shown that HSP27, SOD1, CFL1 and BMP2, did not show any 
significant change in expression levels among all the treatment groups with p > 0.05. While 
the change in gene expression of the other four genes, IL1A, IL8, FOSL1 and HSPA1A 
were significantly different among the control and treatment groups (p < 0.05), which were 
further plotted in Figure 3.2.  
From Figure 3.2, GHK and GHK-Cu at 58 µM and 580 µM did not induce any significant 
change in the expression of all the tested genes compared to control (p < 0.05).  
For CuCl2 and Cu(OAc)2, the gene expression levels were concentration dependent, where 
treatment concentration of 580 µM induced a higher expression of genes than that of 58 
µM. At 58 µM, CuCl2 and Cu(OAc)2 did not induce any significant upregulation of the 
four genes. After treating HaCaT cells with 580 µM CuCl2 or Cu(OAc)2, the expression of 
IL1A, IL8, HSPA1A and FOSL1 were significantly higher than that in the control group, 




of IL8 up to 44 times. At the same concentration of 580 µM, Cu(OAc)2 induced a higher 
regulation of IL1A than CuCl2, while CuCl2 induced a higher regulation of IL8, HSPA1A 
and FOSL1 than Cu(OAc)2. 
Table 3.3 The fold change in gene levels after treatment. * p < 0.05, is considered to be 























































































































































Figure 3.2 Real-time PCR analysis on expression of IL1A (A), IL8 (B), HSPA1A (C), 
FOSL1 (D) following treatment for 24 h in HaCaT keratinocytes. The fold change was 
calculated as the normalized ratio in treatment cells compared to that in control. ANOVA 
was performed between the control and treatment groups for each gene followed by 





3.3.4. Measurement of protein expression by ELISA 
The extracellular content and release of IL-1α, IL-8, HSPA1A and FOSL1 were determined 
using ELISA. The expression of FOSL1 in the culture medium of all samples were not 
detectable. The concentrations of IL-1α, IL-8 and HSPA1A released after treatment with 
various compounds were presented in Figure 3.3.  
At the two tested concentrations, treatment with both GHK and GHK-Cu did not 
significantly increase the IL-1α, IL-8 and HSPA1A protein level.  For the treatment groups 
with CuCl2 and Cu(OAc)2, copper compounds had a positive correlation with the protein 
level regulated.  
CuCl2 didn’t cause any change in the IL-1α, IL-8 and HSPA1A protein levels at the 
concentration of 58 µM, while the protein levels upregulated significantly with 580 µM 
CuCl2 treatment. On the other hand, the IL-1α, IL-8 and HSPA1A protein levels were 
increased significantly with 580 µM Cu(OAc)2 treatment as well. At the same 
concentration of 580 µM, Cu(OAc)2 induced a higher regulation of IL-1α than CuCl2, while 
CuCl2 induced a higher regulation of IL-8, HSPA1A and FOSL1 than Cu(OAc)2. 





Figure 3.3 Concentration of IL-1α (A), IL-8 (B) and HSPA1A (C) in cell culture medium 
quantified by ELISA. Results were presented as pictogram or nanogram of mediator 
released per milliliter of conditioned medium. ANOVA was performed between the control 
and treatment groups followed by Tukey’s post hoc test. * p < 0.05, is considered to be 
statistically significant compared with control. 
3.4.  Discussion 
Keratinocytes make up 95 % of the cells in the epidermis and play an integral role in 




cell line closely resembles normal keratinocytes in their growth and differentiation 
characteristics and hence allows the accurate prediction of response after treatment (157, 
158). After exposure to an irritant, the irritant will exert toxic effects on keratinocytes. This 
will activate the body’s innate immunity with the release of cytokines such as IL-1α in the 
keratinocytes. In turn, these cytokines will activate Langerhans cells, dermal dendritic cells 
and endothelial cells, which contribute to cellular recruitment to the site of damage. 
Neutrophils, lymphocytes and macrophages will then release and further promote an 
inflammatory cascade (159). These will lead to various signs and symptoms of irritation 
such as itch, erythema, edema and pain. By monitoring the inflammatory response 
pathways such as cytokine secretion and receptor activation, various biomarkers can give 
us an indication of the possibility of a safe and efficient transportation of copper through 
the skin to exert its beneficial effects.  
Currently, endpoint measurements are related to severe cell damage such as tetrazolium 
reduction assays to detect viable cells and IL-1α release as inflammatory marker (157). 
Important early changes occur before severe cell damage but no universal markers have 
been identified (157). The search for new parameters or endpoints is necessary given the 
complexity of skin irritation mechanism. Various potential biomarkers have been studied 
and identified using proteomics and toxicogenomics technologies (153, 154, 160). These 
parameters will allow the setup of an in vitro test system, which resembles the in vivo 
situation as much as possible (161).  
Copper is an essential mineral and has many potential benefits in skin growth and activity 
(110). Copper delivery through skin has many potential applications and thus is widely 
studied, including the evaluation of the penetration ability of copper peptides(122), 
biocompatibility of copper containing IUD (136), the enhancement of skin absorption 




safety associated with copper delivery through skin needs to be established. In this study, 
we investigated the skin toxicity of copper compounds using a cell-based in vitro test and 
evaluated the expression of various cytokines at genomic and proteomic levels to discover 
irritancy biomarkers suitable for the evaluation of copper compounds. 
Before the cell testing, we analyzed the pH of the samples tested and it excluded the pH of 
copper compounds as the influencing factor of their potential toxicity (Table 3.2). 
Subsequently, the viability of HaCaT keratinocytes were assessed using MTT assay after 
treatment with test compounds, GHK, GHK-Cu, CuCl2 and Cu(OAc)2. Cultured human 
keratinocytes have been suggested as good models to predict dermal irritancy of substances 
in human subjects (162). The material required for primary keratinocyte culture is limited 
and variable; and the susceptibility to irritants varies with the number of passages. On the 
other hand, the non-tumorigenic, spontaneously immortalized keratinocyte cell line - 
HaCaT cells can provide almost unlimited supply of identical cells, ensuring high intra- 
and inter-laboratory reproducibility. Besides, in vitro cytotoxicity with HaCaT 
keratinocytes and human in vivo data was well correlated (158, 163, 164). HaCaT 
keratinocytes also have been proven to be good candidates for assessing skin irritancy and 
toxicity in conventional monolayer assays measuring using MTT reduction as the viability 
endpoint (157).  
MTT assay mainly reflects the damage to mitochondria; and it is commonly used for in 
vitro cytotoxicity (including skin irritation) measurement. Our result indicated that neither 
GHK nor GHK-Cu showed cytotoxic activity after 72 hours exposure to HaCaT cells. 
CuCl2 and Cu(OAc)2 were only found to be cytotoxic at 5800 µM and cell viability 
decreased significantly after 48 h treatment at 580 µM.  At 58 µM and 580 µM, cytotoxicity 
was not observed following 24 h treatment with all the samples. Another study with CuCl2 




event associated with copper toxicity to Hep G2 cells while lysosomal damage is the early 
event and plasma damage a late feature associated with copper toxicity (165). Considering 
the copper associated mitochondrial toxicity may have delay in the toxicity process, we 
further explored the skin irritation related biomarker change at the genomic level. In 
response to chemical stress, keratinocytes produce and release inflammatory cytokines, 
chemokines and other signaling markers that rapidly generate cutaneous inflammation 
(166). Among the genes tested, expression levels of genes were not significantly different 
in GHK and GHK-Cu group as compared to control. However, we found that four genes, 
IL1A, IL8, HSPA1A and FOSL1, were significantly induced by CuCl2 and Cu(OAc)2 
without inhibiting the cell viability. The protein expression of the four genes in culture 
medium were further tested with ELISA kits. While FOSL1 was not detectable for all 
samples in the ELISA test, the protein level regulation of IL-1α, IL-8 and HSPA1A by the 
copper compounds was similar with the gene level regulation. GHK and GHK-Cu didn’t 
cause any significant change in the extracellular protein concentration of IL-1α, IL8 and 
HSPA1A. However, CuCl2 and Cu(OAc)2 significantly upregulated the extracellular 
protein expression of the three genes at concentration of 58 µM/580 µM without inhibiting 
the cell viability after 24 h. 
Cytokine production and response are important as it participates in immune and 
inflammatory response.  Specifically, IL-1α is constitutively produced and retained in 
keratinocytes, but in response to several stimuli, IL-1α is released, which is an essentially 
primary event inflammation. Triggers of IL-1α production have been observed including 
different stimulus, such as sulfur mustard, nickel, contact allergens or superantigens (167). 
IL-1α stimulates further release of secondary mediators, including IL-8. IL-8 is a powerful 
neutrophil attractant, and is one of the major mediators of the inflammatory response.  It 




damaged tissues (168). Enhanced IL-8 expression of both normal human keratinocytes and 
HaCaT cells were observed after stimulation in vitro by irritant, sensitizer and tolerogen. 
It indicated that IL-8 may play a critical role in the early response to immunogenic and 
inflammatory signals with its response to nonspecific stimuli (169). It was suggested that 
the differentiated production of IL-1α and IL-8 may be linked to the type of product applied 
either irritant or sensitizer (170, 171). Our study showed that CuCl2 and Cu(OAc)2 can 
significantly upregulate HaCaT cell expression of IL-1α and IL-8 in both gene level and 
protein level. The highest fold change in gene level, approximately 44 times higher in IL-
8 expression was observed in 580 µM CuCl2 treated cells when compared to that in control. 
The upregulation of these cytokines will activate and promote an inflammatory cascade, 
leading to various signs and symptoms.  
Besides the interleukin family, other genes related to the skin inflammatory mechanism 
were also observed to be upregulated. FOSL1 is an early gene that belongs to the activator 
protein 1 family of dimeric transcription factor genes (172). It plays a role in the 
angiogenesis and vasculogenesis processes, where it regulates the expression of key 
molecules on the cell surface to modulate cell adhesion and motility (173). While HSPA1A 
belongs to the HSP70 family of heat shock proteins, it can be highly activated by various 
stressful stimulus, where it is required for refolding of damaged and unfolded proteins 
generated by stressful conditions (174). Both FOSL1 and HSPA1A are stress-inducible 
and our results showed that they were significantly upregulated in the presence of CuCl2 
and Cu(OAc)2. Hence, FOSL1 and HSPA1A can potentially serve as useful inflammatory 
markers for copper compounds. 
We have also studied other genes, SOD1, CFL1, BMP2 and HSP27 that were previously 
shown to be upregulated in the presence of sodium lauryl sulfate by DNA array or 




upregulation were observed after treatment with various copper compounds (Table 3.3). 
In previous studies, human keratinocytes, human epidermis model and human 
reconstructed skin model were used for testing the response of sodium lauryl sulfate. These 
new endpoints have not been widely validated for skin irritation responses. Our study may 
prove that these endpoints are not sufficient for irritancy testing of copper compounds in a 
monolayer HaCaT assay. 
Copper delivery through skin can potentially be useful. However, the choice of copper 
compound is important. At the same concentration, different copper compounds can exhibit 
different irritancy potential. From our results, we observed that GHK-Cu exhibits low 
potential of inducing skin irritation response in comparison with CuCl2 and Cu(OAc)2. 
GHK-Cu can potentially be useful in providing a safe delivery of copper through the skin 
to exert its beneficial effects. Copper salts are discouraged from the direct administration 
on skin due to its irritancy potential and toxicity. There are several mechanisms proposed 
in attempt to explain copper irritancy. Copper may become potential irritants when they 
are oxidized and causes the formation of free acids. It is the oxidizing action of such acids 
that potentially result in skin irritation reactions once they reach the viable skin layers (137). 
It can also interact with reduced oxygen species to form hydroxyl radical that inactivates 
enzymes and disrupts the membranes and organelles (175). 
Interestingly, GHK-Cu did not show any signs of irritation. This may be due to the 
complexation of copper with peptide GHK (176). When GHK is coupled with copper, the 
peptide may silence the redox activity of copper, facilitating the non-toxic delivery of 
copper into the cells (114). Complexation using other ligands can be explored but GHK is 
commonly used as it has additional cosmetically intriguing activities such as stimulation 
of collagen synthesis, chemotaxis, anti-stinging effects and others (177). Our results also 




related biomarkers, which provides an additional benefit when used for complexation with 
copper.  
Accurate evaluation of cosmetological, dermatological and pharmaceutical products after 
application on human skin are both essential and crucial in product development. In vitro 
skin irritation test provides an alternative to animal testing and allows the screening of 
compounds before they undergo clinical testing. The current standard operating procedure 
by ECVAM recommends the use of MTT reduction as parameter to make prediction on 
the skin irritancy of substances using EpiSkinTM test method, while IL-1α endpoint is 
regarded as an useful adjunct to MTT assay (178). However, measuring cytotoxicity alone 
is not sufficient. We have shown that CuCl2 and Cu(OAc)2 irritation induces the 
upregulation of various genes without the concomitant inhibition of cell viability. To 
provide a more accurate prediction of skin irritancy potential of the test compound, in vitro 
skin irritation test can include other potential biomarkers.  
In this study, we evaluated various copper compounds at cellular, genomic and proteomic 
levels using HaCaT keratinocytes. For the first time, we have shown that different types of 
copper compounds have different irritancy potential at three different levels. Specifically, 
GHK-Cu was found to be least possible to cause skin irritation, while CuCl2 and Cu(OAc)2 
were found to induce the expression of various skin irritation biomarkers. These 
biomarkers can be used in adjunct to MTT assay for a more accurate prediction of the in 
vivo response. This irritancy test approach may be extended to other similar compounds or 
minerals and can potentially predict the in vivo skin irritation response. 
Further investigations can include a validation study of the genes involved in the skin 




safety of GHK-Cu on human subjects. This will allow us to determine the correlation of 
the in vitro results with the actual in vivo response.  
3.5. Conclusion 
In this study, we have demonstrated that copper peptide has a low potential of inducing 
skin irritation response when compared to copper chloride and copper acetate. In vitro skin 
irritation test with sensitive endpoints is a possible alternative to animal testing. IL-1α, IL-
8, FOSL1, and HSPA1A are potential in vitro biomarkers that can be used in adjunct to 
MTT assay in identifying irritants and assessing the low skin irritation potential of copper 
compounds. This irritancy test approach may also be useful to assess the skin irritancy 
potential of other similar inorganic compounds or minerals and can potentially provide an 






Chapter 4 High durability and low toxicity antimicrobial 
coatings fabricated by quaternary ammonium silane 
copolymers 
(Adapted from Biomaterials Science. 2016, 4(2), 299-309) 
4.1. Introduction 
Adhesion and subsequent growth of microorganisms form biofilms, which presents as a 
great concern in various areas, such as biomedical devices, health care applications, water 
purification systems, dental surgery equipment, food packaging, textiles, household 
sanitation, etc (179, 180). They can cause contamination of products and corrosion. 
Microbial colonization of biomaterials can also lead to the systemic and implant-associated 
infections, the incidence of which is expected to increase with the expansion of new 
biomedical devices (181). It was reported that microorganisms in biofilm are more resistant 
to disinfection at an extent of up to 1000 times compared to free-floating microorganisms 
(182). Therefore, it is imperative that microbial growth can be more efficiently inhibited in 
the early stage of microbial adhesion and proliferation (183).  
In recent years, antimicrobial polymers have attracted considerable interests from both 
academia and industry, owing to their advantages over small molecular biocides, being 
non-volatile, increased stability, low toxicity, minimal permeability though skin and the 
potential to maintain long-term activity (184). Researchers have tried to immobilize 
surfaces with polymers to prevent the formation of biofilms, thus avoiding the spread of 
diseases and material deterioration. The reported techniques to attach polymers to surfaces 
include chemical grafting techniques, layer-by-layer and surface-initiated polymerization 




polymers can produce non-leachable antimicrobial surface which can remain permanently 
antimicrobial (184).  
Highly hydrophilic polymers have been grafted to biomaterials to prevent biofilm 
formation by repelling microbes and preventing their attachment. Such polymers include 
poly(ethylene glycol) derivatives and poly(ethylene oxide), both of which display an 
exclusion volume effect which renders them capable of resisting non-specific protein 
adsorption and cell adhesion (188). However, these polymer coatings are anti-adhesion 
based and don’t have any biocidal activity. Microorganisms may be introduced into the 
patient during implantation procedures and the failure of these polymers to eliminate them 
can result in implant failure (189).  
The antimicrobial surfaces can be further modified to kill microbes in the vicinity by 
conjugating polymer with agents such as antibiotics or antimicrobial peptides or complexed 
with silver (190-194). Wach et al. synthesized a hybrid molecule comprising a 
poly(ethylene glycol) chain with an anachelin chromophore at one end for the 
functionalization of surfaces and an antibiotic, vancomycin at the other responsible for 
antimicrobial activity (195). Penicillin has also been tethered to different surfaces by 
attaching to poly(2-hydroxyethyl methacrylate) chains and poly(ethylene glycol) chains. 
But the antibiotics may partially lose due to hydrolysis (196-198). Ramstedt et al. reported 
the synthesis of poly(3-sulfopropylmethacrylate) brushes onto gold and Si/SiO2 surfaces 
by transfer radical polymerization, and the polymer brushes can easily load with silver ions 
to exert the antibacterial activity (191). Silver nanoparticles were loaded on decorated 
cellulose filter papers grafted with poly(tert-butyl acrylate) polymers, showing excellent 
antibacterial properties against E. coli (199). However, the bactericidal action of silver 
relies to a certain extent on the leaching of the ions, which may cause certain environment 




conjugated with antimicrobial proteins (AMPs) (194).  AMPs are of great interest to study 
in recent years because they have a low propensity for developing microbial resistance 
(192). Covalent immobilization of AMPs onto surface can increase their long-term stability 
while decreasing their cytotoxicity associated with higher concentrations of soluble 
peptides when compared to leach- or release-methodologies (200, 201). A common 
approach to covalently immobilize AMPs involves the use of functionalized resins such as 
poly(ethylene glycol) spacers or other polymeric ‘brushes’ with reactive groups suitable 
for peptide covalent conjugation. However, the antimicrobial activity of AMPs decreased 
after immobilization in many reported studies (202-204). The immobilization parameters, 
such as peptide surface concentration, influence of the spacer (length and flexibility) or 
peptide orientation after immobilization, must be optimized to obtain efficient, safe, and 
long-lasting antibacterial coatings (205). Furthermore, the cost and complexity of their 
synthesis and immobilization add up to the disadvantages of AMPs as well. 
A third class of antimicrobial polymeric surfaces was created by immobilizing bactericidal 
polymer chain to kill the bacteria upon contact (184). These polymers usually contain 
cationic groups, such as quaternary ammonium or phosphonium groups. Tiller et al. 
reported poly(vinyl-N-pyridinium bromide) modified surfaces exhibiting good 
antibacterial properties, but the complicated method may limit it from routine practices 
(206). Lee et al. grafted an antibacterial quaternary ammonium polymer directly on the 
surface of the glass using atom transfer radical polymerization, but this approach lacks the 
ease of implementation as well (207). On the other hand, quaternary ammonium siliane 
(QAS) monomeric agents, such as trimethoxysilyl and trihydroxysilyl quaternary 
ammonium compounds, have been used to prepare antibacterial surfaces easily by covalent 
attachment to a surface through reaction of the trimethoxysilyl groups with surface silanol 




treatments in human clothing and bedding, household areas, carpets and upholstery. QAS 
agents have the largest consumption volume as textile antimicrobials compared with 
triclosan and silver (209). They are also used as material preservatives in the manufacturing 
of paints, coatings, and concretes.  However, despite the widespread use of QAS agents, 
severe toxicity has been observed with regard to skin and eye irritations (210) and contact 
dermatitis was also reported with the QAS coating (211, 212). Besides, the in-situ 
condensation coating on the surface was supposed to form a monomolecular layer and it 
may not be resistant to abrasion. The antimicrobial activity is lost after the surface layer is 
worn off.  
 To address these problems, we have synthesized novel QAS antimicrobial copolymers via 
a simple free radical addition reaction and an abrasion-resistant antimicrobial surface can 
be further prepared by a simple and easy thermal-curing process. The synthesized 
copolymers were found to be less toxic to human cell lines than a commercial antimicrobial 
QAS monomeric agent, namely, dimethyloctadecyl [3-(trimethoxysilyl)propyl] 
ammonium chloride (DTPAC). The QAS antimicrobial copolymer coatings demonstrated 
a broader antimicrobial activity and a better durability than those formed by DTPAC. We 
envision that, with a low toxicity and enhanced durability, the new QAS copolymers are 
appealing and represent a better substitute for the current monomeric QAS coatings. 
4.2. Materials and methods 
4.2.1. Materials 
The monomers used for PMT copolymer synthesis are [3-
(methacryloylamino)propyl]trimethyl ammonium chloride (MAPTAC, 50wt% in H2O, 
Sigma-Aldrich) and 3-trimethylsilylpropyl methacrylate (TMSPMA, Sigma-Aldrich). 5-




were used for synthesis of another antimicrobial monomer DMA-C16Br. Potassium 
persulfate (K2S2O8, Sigma-Aldrich) and 2,2’-Azobis(2-methylpropionitrile) (AIBN, 
DuPont, USA) were employed as free radical initiator for polymerization and acetone 
(Merck) was used to precipitate the synthesized polymers. A commercialized antimicrobial 
agent, DTPAC (42 wt% in methanol, Sigma-Aldrich) was used as a positive control in the 
antimicrobial test of coatings. Acetic acid (Merck) was used to prepare the acidic solution 
for QAS polymers’ hydrolysis. The bacteria were grown in nutrient broth (Neogen, USA) 
and on nutrient agar prepared from bacteriological agar (Neogen, USA). The fungus was 
grown in tryptone soya broth (Neogen, USA) and on tryptone soya agar (Neogen, USA). 
The source of materials for cell culture were same with that used in Chapter 2.  
4.2.2. Synthesis of MAPTAC based QAS copolymers 
QAS copolymers PMT-5% and PMT-10% were synthesized from the monomers 
MAPTAC and TMSPMA in the presence of 1wt% K2S2O8. PMT-5% was synthesized from 
the monomer weight ratio of 95% MAPTAC (19.0 g) to 5% TMSPMA (0.5 g) while PMT-
10% was synthesized from 90% MAPTAC (18.0 g) to 10% TMSPMA (1.0 g). 
Homopolymer PMAPTAC was synthesized from MAPTAC (20.0 g) in the presence of 1 
wt% K2S2O8. The reaction proceeded at 70 °C with 400 rpm stirring speed for 1 hour. 
Thereafter, 15 ml of water was added to terminate the reaction and decrease the viscosity 
of the mixture. The resulted copolymers and homopolymer were precipitated against 
acetone (3 times) and vacuum dried at 50 °C for 48 hours.  
4.2.3. Synthesis of [2-(methacryloyloxy)ethyl]dimethylhexadecylammonium 
bromide (DMA-C16Br) and its corresponding QAS copolymer 
In-house synthesis of DMA-C16Br monomer was performed in accordance to literature 




Aldrich, Singapore) were mixed in a 100 ml flask using magnetic stirrer purged with 
nitrogen gas for 5 minutes. Hydroquinone (100 mg) was added to prevent spontaneous 
radical polymerization of DMA. The reaction flask was then placed in a 50˚C water bath 
and stirred continuously for 12 hours. The white-grey precipitate was filtered from the 
reaction mixture and washed with 100 ml of cold diethyl ether three times to remove 
unreacted reactants. The final product was recrystallized using acetone and dried under 
vacuum at room temperature with 85% yield. The newly synthesized DMA-C16Br was 
characterized by 1H-NMR (CDCl3, δ ppm) of 5.6 (Ha, 1 H), 6.1 (Hb, 1 H), 1.9 (Hc, 3 H), 
4.6 (Hd, 2 H), 4.1 (He, 2 H), 3.5 (Hf, 6 H), 3.6 (Hg, 2 H), 1.3 (Hh, 28 H), 0.8 (Hi, 3 H) 
(Figure 4.1). Infrared spectroscopy analysis was also consistent with structure of DMA-
C16Br (Figure 4.2).  
 
Figure 4.1 1H-NMR (CDCl3, δ ppm) characterization of DMA-C16Br : 5.6 (Ha, 1 H), 6.1 
(Hb, 1 H), 1.9 (Hc, 3 H), 4.6 (Hd, 2 H), 4.1 (He, 2 H), 3.5 (Hf, 6 H), 3.6 (Hg, 2 H), 1.3 (Hh, 





Figure 4.2 ATR-FTIR spectrum of DMA-C16Br. 
QAS copolymer PDT-10% was synthesized from DMA-C16Br and TMSPMA in the 
presence of AIBN. A 50 ml Schlenk flask equipped with a magnetic stirrer was connected 
to a vacuum line, and the moisture was removed by heating under vacuum. When the flask 
was cooled down, dry nitrogen was filled in. Under a nitrogen atmosphere, DMA-C16Br (2 
g), isopropanol (10 g), and AIBN (0.05 g) were added into the flask that was tightly sealed 
with a rubber septum. The mixture was then heated to 90 °C and stirred constantly at 400 
rpm. During the heating process, 150 ml TMSPMA (0.15 g) was injected into the flask 
dropwise, and the reaction was allowed to proceed for 1 hour before adding another 150 
ml TMSPMA. After 2 hours, a combination including DMA-C16Br (1.25 g), isopropanol 
(5 g), and AIBN (0.05 g) was purged and injected into the flask, followed by adding 100 
ml TMSPMA dropwise. The same composition of DMA-C16Br, isopropanol, AIBN, and 




heated for 12 hours at 90 °C with stirring. Thereafter, another 0.05 g AIBN was added to 
achieve a high monomer conversion and the polymerization was terminated 2 hours later. 
Final solution was dropped into excess amount of cold diethyl ether to precipitate PDT-
10%. The dissolution-precipitation cycle was repeated for two times to remove the residual 
monomers. The obtained viscous product was isolated and dried under vacuum.  
4.2.4. Preparation of QAS copolymer coatings 
Glass slides (25.4 × 76.2 mm, Continental Laboratory Products, USA) were used as the 
substrates to study the coating process of PMT-5%, PMT-10% and PDT-10%. Prior to 
coating, the glass slides were immersed in 10% sodium hydroxide for 1 hour, thoroughly 
rinsed with water and cleaned with 96% ethanol before air drying. 10 mg/ml of PMT-5% 
and PMT-10% solution was prepared by dissolving in a pH 2.5 acetic acid solution, 
respectively. 5 mg/ml PDT-10% was solubilized in a mixture containing 90% of 
isopropanol and 10% of acetic acid solution (pH 2.5) following by heating at 50 ˚C for 30 
min. 5 mg/ml and 10 mg/ml DTPAC was prepared in acetic acid solution (pH 2.5). An 
acidic condition can help hydrolyze the silyl ether to corresponding reactive silanol groups 
in copolymers. PMT-5%, PMT-10% and DTPAC solution was transferred to the pre-
treated glass slide by 29 µl/cm2 and spread evenly using a pipette. PDT-10% solution has 
a good spreadability on glass slide and thus 20 µl/cm2 was pipetted on the glass slide for 
coating. Crosslinking of silanol groups to form siloxane linkage was initiated by drying the 
substrate at 130 °C for 30 minutes. 
4.2.5. Characterization of QAS copolymers and coatings 
A Spectrum 100 FTIR spectrophotometer (PerkinElmer, USA) with an ATR set-up was 
used to monitor the polymer synthesis, hydrolysis and crosslinking reactions. Infrared 




Water contact angle was measured with a static contact angle measurement device 
(Attension, BiolinScientific). The machine was equipped with a digital camera, automatic 
liquid dispensers, and sample stage allowing hands-free contact angle measurement via 
automated placement of a drop of water. The drop shape is captured automatically and then 
analyzed via OneAttension software to determine the static contact angle.  
Mass loss of synthesized polymers, weighing approximately 10 mg, were measured by 
thermogravimetric analysis (TGA), using a TGA-Q5000 apparatus (TA Instruments Ltd, 
USA). The samples were heated from room temperature to 600 °C at 10 °C/min in a 
nitrogen gas flow of 20 cm3/min. 
After coating, glass slides were subjected to abrasion test by using a Taber Linear Abraser 
5750 instrument with a vertical load of 1 kg, and 10 cycles were performed with a 
magnitude of 1 inch. The characteristic peak absorbance from ATR-FTIR examination of 
coating before and after abrasion at the same location was used to calculate the retention 
of coating on the glass slides. The retention of coating was expressed as the peak height of 
the characteristic peaks before abrasion divided by that of after abrasion.  
4.2.6. Antimicrobial assays of QAS copolymers and coatings 
15% glycerol cell stocks of Staphylococcus aureus (S. aureus, ATCC 6538P, Oxoid, 
Singapore), Escherichia coli (E. coli, ATCC 8739, Oxoid, Singapore) and Candida 
albicans (C. albicans, ATCC 2091, MicroBiologics, France) were prepared and divided 
into aliquots and frozen at -80 °C. All microbes were prepared from the stocks and were 
growth to their exponential phase before they were harvested for antimicrobial assays. S. 
aureus and E. coli were grown in nutrient broth (Acumedia, Michigan) at 37 ˚C with 





 The minimum inhibitory concentration (MIC) assay was carried out via the broth 
microdilution method using sterile 96-well flat-bottomed microplates (Costar, Corning, 
USA). S. aureus (Gram-positive), E. coli (Gram-negative)  and C. albicans (fungus) were 
grown to their exponential phase and appropriately diluted to achieve the inoculum size of 
approximately 105 colony forming units (CFU)/ml in each well. MAPTAC homopolymer 
(PMAPTAC), PMT-5% and PMT-10% were dissolved in sterile PBS to get a concentration 
of 5 mg/ml. 2.5 mg/ml PDT-10% was prepared in 50% DMSO. Then the copolymer 
solutions were sterilized via filtration with a 0.20 µm filter and serially diluted with PBS 
(water for PDT-10% dilution) to achieve a broad range of polymer concentrations. 20 µl 
polymer solution with different concentrations was added to 180 µl inoculum in each well. 
The microplate was incubated at 37 °C (for bacteria)/28 °C (for fungus) with shaking at 
200 rpm for 24 hours before being assayed at 600 nm using a microplate reader (Tecan, 
Switzerland). The MIC is defined as the lowest polymer concentration at which there is no 
increase in optical density. Sterile broth, sterile polymer solutions of various concentrations 
dissolved in broth, and broth containing microorganism with different DMSO 
concentrations were used as controls. After the microplate used in the MIC assay has been 
incubated for 24 hours, minimum bactericidal/fungicidal concentration (MBC/MFC) 
determination was done for concentrations at and above MIC. Briefly, a 100 µl aliquot was 
removed from each well showing no growth except wells containing the sterility controls. 
Each aliquot was plated onto nutrient agar in duplicate and incubated at 37 °C at least for 
24 hours (or plated onto tryptone soya agar plates and incubated at 28 °C for 3 days for C. 
albicans) before conducting a colony count. MBC/MFC is defined as the lowest 
concentration that achieves a ≥ 99.9% or a three-log reduction in the initial MIC inoculum 
within 24 hours. This was determined by calculating the maximum allowable number of 
colonies per plate. The rejection value (CFU/plate) was expressed as initial inoculum 




The test for antimicrobial activity of the polymers’ coating was further conducted on glass 
cover slip (Menzel-Gläser, Germany) (214, 215). Before coating, glass cover slips were 
treated in the same way as glass slides previously described in the method part. The treated 
surfaces of cover slips (22 × 22 mm) were covered with acidified PMT-5% (10 mg/ml), 
PMT-10% (10 mg/ml) and DTPAC solutions ( 5 and 10 mg/ml) at 29 µl/cm2, while covered 
with acidified PDT-10% at 20 µl/cm2 due to its good wettability, respectively. Then the 
cover slips were dried at 130 °C for 30 minutes. For antimicrobial assessment of coatings, 
the microorganisms were grown to their exponential phase and appropriately diluted to 
achieve the standard inoculum size between 9×105 to 106 CFU/ml. Then coated substrate 
was placed in sterile Petri dish and appropriate amount of bacteria inoculum was dropped 
on the surface, then it was covered with a plastic film (18 × 18 mm) to achieve the inoculum 
amount at least 104 cells per 1 cm2 cover film. Uncoated substrates were used as controls. 
Inoculated bacteria were recovered by removing the film-covered substrates and placing 
them into 50 ml Falcon tubes containing 10 ml of PBS. The tubes were vortexed for 1 
minute before serially diluting the samples in PBS. A viable count was conducted using 
the spread plate method after appropriate dilution. Bacteria recovery was carried out after 
incubation at 37 °C in humidified condition for 24 hours while incubation temperature of 
28 °C was used for C. albicans. The unit number of viable microbes was obtained from the 
counts the colonies calculated according to following equation: 
N = C×D×V/A 
Where, N: Number of viable microbe per 1 cm2. C: Count of colonies. If C <1, C is taken 
as 1. D: Dilution factor. V: Volume of recovery solution. A: Area of cover film (cm2).  The 
antimicrobial activity was expressed as log reduction number of the microorganisms after 




4.2.7. Cytotoxicity assay  
The cytotoxicity of the polymers was evaluated via the determination of mitochondrial 
succinate dehydrogenase activity using MTT assay with HDF, HaCaT keratinocytes and 
human embryonic kidney 293 (HEK293) cells. PMAPTAC, PMT-5%, PMT-10% and 
DTPAC were dissolved in PBS with a concentration of 2.5 mg/ml, sterilized via filtration 
and further diluted with PBS to the desired concentrations. On the other hand, 2.5 mg/ml 
PDT-10% in 50% DMSO solution were sterilized via filtration and serially diluted two-
fold with sterile water. Cells were seeded at a density of 104 cells per well in 96-well flat-
bottomed microplates (Costar, Corning) and incubated with DMEM culture medium 
(supplemented with 10% FBS and 1% penicillin-streptomycin solution) for 24 hours. 
Thereafter, the culture medium was replaced with 180 µl of fresh medium and 20 µl of 
polymer solution in each well. The cells were incubated with the different concentrations 
of polymers and DTPAC for 24 hours at 37 °C, 5% CO2 and 95% relative humidity before 
removal of the medium. 200 µl of fresh medium and 20 µl of filtered MTT solution (5 
mg/ml in PBS) were further added and incubated with the cells for another 4 hours at 37 °C. 
Then, the supernatant was removed by aspiration, and resultant formazan crystals were 
dissolved in DMSO with shaking. The absorbance at 595 nm (A595) was measured using a 
microplate reader (Tecan, Switzerland). Wells containing DMSO alone were used as a 
blank, and cells treated with PBS alone were used as control for the assay. Relative cell 
viability was expressed as (A595 sample ─ A595 DMSO)/ (A595 control ─ A595 DMSO) × 
100%. For each sample, the final absorbance was the average of those measured from six 
wells in parallel. Since DTPAC was provided in 42 wt% in methanol and DMSO was used 
as solvent system for PDT-10% solution preparation, the toxicity of methanol and DMSO 




same concentrations in tested DTPAC solutions and DMSO with the same concentrations 
in tested PDT-10% solutions showed no significant difference with control.  
4.2.8. Statistical analysis 
Statistical analysis was performed by ANOVA followed by Tukey’s post-hoc test. The 
difference was considered to be significant at p-value < 0.05. 
4.3. Results 
4.3.1. Fabrication and characterization of QAS copolymers and coatings 
Figure 4.3A illustrates the reaction scheme for the synthesis of QAS copolymers from two 
monomers, namely, [3-(methacryloylamino)propyl]trimethyl ammonium chloride 
(MAPTAC) and 3-trimethylsilylpropyl methacrylate (TMSPMA), with two different 
weight ratios. The synthesized copolymers, named PMT-5% and PMT-10%, derive their 
antimicrobial properties from the cationic quaternary ammonium group in MAPTAC while 
utilizing the silane functionality in TMSPMA as an anchor. K2S2O8 functions as a free 
radical initiator for polymerization which proceeds via a free radical addition reaction 
involving the saturation of the α,β-unsaturated amide in MAPTAC and the α,β-unsaturated 
ester in TMSPMA. The unreactive silyl ether acts as a protective group for the silane 
functionality during this reaction. Subsequently, it is activated via hydrolysis in acidic 
medium which was achieved by dissolving the polymers in pH 2.5 acetic acid solutions. 
This yielded highly reactive silanol groups which readily undergo dehydration reactions 
involving the loss of water. Drying the acidified polymer solution under high temperatures 
of 130 °C gave rise to the formation of siloxane crosslinking amongst polymers as well as 
between polymers and the substrate surfaces where reactive groups present. Similarly, 




process from DMA-C16Br and TMSPMA with AIBN as a free radical initiator. The 
quaternary ammonium moiety, DMA-C16Br contains a 16-carbons long alkyl chain. The 
water solubility of PDT-10% is not very good, so acidified isopropanol was used to 
dissolve the polymer and facilitate the hydrolysis of silyl ether group. The synthesized 
copolymers appear yellow which is typical of the physical appearance of most QACs (216).  
 
Figure 4.3 Synthesis scheme of QAS copolymers and coatings. (A) PMT-5% and PMT-
10% and their coatings. (B) PDT-10% and its coating. 
The ATR-FTIR spectra were used to monitor the PMT copolymer synthesis, extent of 
hydrolysis and condensation reactions undergone by the copolymers during the coating 
process (Figure 4.4). Characteristic stretches of the Si─O bond in alkoxysilane compounds 
appear as strong bands at 1090 cm-1 and sharp bands around 2840 cm-1 and in the 
copolymers’ spectra, that is 2850 cm-1 in PMT-5%’s spectrum and 2842 cm-1 PMT-10%’s 
spectrum. The Si─O bond of silanol groups showed absorption as a single band at 915 cm-
1. These peaks confirmed the successful polymerization of the copolymers. Changes to the 




inference that copolymer hydrolysis had occurred. Specifically, the disappearance of the 
sharp band at 2850 cm-1 in PMT-5%’s spectra and 2842 cm-1 in PMT-10%’s spectra can 
be observed. There was also a discernible reduction in the intensity of the strong band 
located at 1090 cm-1 in the copolymers’ spectra after coating. As both bands were 
associated with the Si─O stretching vibration of the silyl ether group, these observations 
were consistent with the occurrence of hydrolysis. During the drying process, the formation 
of siloxane crosslink in the copolymer coatings restrained the stretching vibration of the 
carbonyl group in the ester functionality, causing the carbonyl stretch in the 1700 cm-1 
region to disappear. Evidence for the successful crosslinking in the current study was thus 
shown by the disappearance of the carbonyl bands at 1718 cm-1 in PMT-10%’s spectra 
(Figure 4.4B). The reduction of the Si─O bond of silanol groups at 915 cm-1 indicated the 





Figure 4.4 ATR-FTIR spectra of: (A) PMT-5% copolymer and coating; (B) PMT-10% 
copolymer and coating. 
On the other hand, the synthesis of PDT-10% was characterized by the disappearance of 
5.6 ppm and 6.1 ppm peaks in 1H-NMR spectrum of PDT-10% when compared to DMA-
C16Br which corresponds to the terminal vinyl hydrogen (Ha, and Hb) of DMA-C16Br, since 
vinyl carbons of DMA-C16Br and TMAPMA would be saturated as a result of monomers 
joining together during polymerization (Figure 4.5A).  ATR-FTIR spectroscopy was also 
used to monitor the synthesis and coating process of PDT-10%. Characteristic stretches of 
the Si─O bond of methoxysilane (–Si-O-CH3) showed as a strong band at 1089 cm-1 in the 




subjected to hydrolysis and formation of siloxane crosslink during the coating process 
(Figure 4.5B). 
 
Figure 4.5 Characterization of PDT-10% and PDT-10% coating. (A) 1H-NMR spectra 
overlay of DMA-C16Br and PDT-10%. Disappearance of 5.6 and 6.1 ppm peaks on PDT-
10% spectrum, which correspond to the terminal vinyl hydrogen (Ha, and Hb) on DMA-
C16Br, indicated free radical polymerization reaction had taken place. (B) ATR-FTIR 
spectra of PDT-10% copolymer and coating. 
The thermal degradation of QAS polymers was investigated by using thermogravimetric 
analysis (Figure 4.6). The initial degradation temperature of PMAPTMC, PMT-5% and 




temperature of PDT-10% was 214.4 °C. The high degradation temperature indicated high 
thermal stability of the synthesized polymers. 
 
Figure 4.6 TGA of PMPTAC, PMT-5% and PMT-10% and PDT-10%. 
The surface energy and hydrophobicity of QAS coatings were evaluated by static contact 
angle. Figure 4.7 showed the contact angles of PMT-5%, PMT-10%, PDT-10% and the 
commercial antimicrobial agent DTPAC coatings against glass control, which can be 
considered as hydrophilic surface due to the low value (26.1°). The QAS coatings are more 
hydrophobic and have higher contact angle values than the glass control. Furthermore, the 
QAS copolymer PMT-5% and PMT-10% coated glass substrates have even higher contact 






Figure 4.7 (A) Water droplets on the surfaces of uncoated and coated glass. (B) Contact 
angles of the surfaces of uncoated and coated glass. Data represents the standard deviation 
of at least three tested samples. p-value < 0.05 indicates statistically significant, and * 
shows significance between coated samples and control, while ** shows significance 
between different coated samples. 
The durability of the QAS copolymer coatings were evaluated by abrasion test combined 
with ATR-FTIR analysis. As a control, coatings formed by MAPTAC homopolymer 
(PMAPTAC) and the commercial QAS monomeric antimicrobial agent, DTPAC were 
tested.  As shown in Figure 4.8, the PMAPTAC coating shows a low retention of less than 
20%. On the other hand, the corresponding copolymer (PMT-5% and PMT-10%) coatings 
with a silane anchor showed high retention of 81.3% and 92.5%, respectively. The other 
QAS copolymer with a silane anchor, PDT-10%, had a retention of 70.3% after abrasion 
test. It is noted that the coating retention of the monomeric QAS agent DTPAC was 42.5%, 





Figure 4.8 Retention of characteristic peaks of antimicrobial coatings after abrasion test. 
Data represents the standard deviation of three tested samples. p-value < 0.05 indicates 
statistically significant, and * shows significance between the QAS coated samples and 
PMAPTAC coated samples, while ** shows significance between different QAS coated 
samples. 
4.3.2. Antimicrobial efficacy of QAS in solutions 
The antimicrobial activities of the synthesized polymers together with DTPAC were tested 
against Gram-positive bacteria S. aureus, Gram-negative bacteria E. coli and fungus C. 
albicans. As shown in Table 4.1, the synthesized PMT polymers had MICs in the range of 
62.5 to 125 µg/ml against E. coli and S. aureus and > 500 µg/ml against C. albicans. A 
comparison of the antibacterial activity of PMT-5% and PMT-10% to that of PMAPTAC 
revealed a similar minimum inhibitory concentration (MIC) and minimum bactericidal 
concentration (MBC) values of 62.5 µg/ml with the sole exception of PMT-5% displaying 
slightly lower activity against E. coli at 125 µg/ml. The similar MIC of PMAPTAC with 
that of PMT-5% and PMT-10% provided evidence that the copolymerization of quaternary 
ammonium monomer (MAPTAC) with TMSPMA did not affect its antimicrobial activity. 
Another notable aspect of the QAS copolymers’ antimicrobial activity is their comparable 




5% required only a concentration twice its MIC against S. aureus to inhibit the growth of 
E. coli while PMT-10% inhibited the growth of both bacteria at the same concentration. 
On the other hand, although the monomeric QAS agent DTPAC and PDT-10% has a lower 
MIC value against S. aureus than that of the synthesized QAS polymers, their MIC values 
against E. coli are comparable. PDT-10% and DTPACT shared the similar MIC values 
against S. aureus and E. coli. In addition, the MBC:MIC ratios for all the QAS compounds 
and bacteria are ≤ 4, indicating the antimicrobial mechanism of action is bactericidal rather 
than bacteriostatic (217). However, the copolymers were less effective against the fungus 
C. albicans. PMT polymers failed to inhibit fungus growth even at higher concentrations 
of > 500 µg/ml, while PDT-10% and DTPAC showed effective against C. albicans with a 
MIC value of 125 and 15.6 µg/ml, respectively. 
Table 4.1 MIC and MBC/MFC against E. coli, S. aureus and C. albicans at an inoculum 
size of approximately 105 CFU/ml. The unit of the MIC and MBC/MFC values is µg/ml. 
 
4.3.3. Cytotoxicity assay of QAS in solutions 
The cytotoxicity of QAS polymers were tested against HDF, HaCaT keratinocytes and 
HEK293 cell lines. Human cells’ viability predictably decreased with increasing 
concentration of PMAPTAC, PMT-5%, PMT-10%, PDT-10% and DTPAC (Figure 4.9) 
as quaternary ammonium polymers possess membrane-disruption ability (218). Here, 




different QAS compounds. The LC50 values of PMAPTAC, PMT-5% and PMT-10% 
PMT-5% against HDF and HEK 293 cells were all ≥ 62.5 µg/ml, while the value for PDT-
10% and DTPAC were > 31.3 µg/ml and > 15.6 µg/ml, respectively. For the test with 
HaCaT keratinocytes, PMT-5% showed a LC50 value of 31.3 µg/ml, PMAPTAC and 
PMT-10% > 62.5 µg/ml, PDT-10% > 15.6 µg/ml, while DTPACT > 7.81 µg/ml.  
 
Figure 4.9 Relative human cell viability after 24 hours’ exposure to different PMAPTAC, 
PMT-5%, PMT-10%, PDT-10% and DTPAC concentrations: (A) HDF, (B) HaCaT 




4.3.4. Antimicrobial efficacy of QAS coatings 
We further tested the antimicrobial activity of the QAS copolymers when they were coated 
on glass substrates. In comparison, blank glass substrates and coatings formed by the 
monomeric QAS antimicrobial agent, DTPAC were used as controls. 
As shown in Figure 4.10, the QAS coatings of PMT-5% (10 mg/ml), PMT-10% (10 
mg/ml), PDT-10% (5 mg/ml) and DTPAC (10 mg/ml) were all very effective against S. 
aureus and E. coli with log reduction values higher than 4. In fact, there were no viable 
bacterial recovered from all the QAS coated samples after 24 hours. However, when a 
lower concentration of DTPAC (5 mg/ml) was used for the coating, the resulting coating 
was still very effective (with log reduction value higher than 4) against S. aureus but less 
effective against E. coli (with log reduction value of 1.5). On the other hand, the 
antimicrobial activities (i.e., log reduction value) of PMT-5% (10 mg/ml), PMT-10% (10 
mg/ml) and PDT-10% (5 mg/ml) coatings against C. albicans were all no less than 2, while 
the values of DTPAC coatings were only 0.2 no matter the concentration of coating 
solution is 10 mg/ml or 5 mg/ml. According to the test for measuring the antimicrobial 
activity of surfaces, significant antimicrobial effectiveness is defined as antimicrobial 
activity ≥ 2.0 after 24 hours. Therefore, QAS copolymeric coatings showed significant 
antimicrobial effectiveness against all the three microorganisms, while DTPAC were only 





Figure 4.10 Viable microbial counts of QAS coatings against S. aureus, E. coli and C. 
albicans after 24 hours of exposure to coated glass cover slips (A) and the corresponding 
numeric values of log reduction (B). 
4.4. Discussion 
Microbial contamination and subsequent biofilm formation is a major cause of 
infection, contamination, and product deterioration. Considering it is very difficult 
to remove the biofilm after its formation, a useful strategy is to prevent biofilm 
formation before it starts. QAS agents can be used to coat various substrates to 
impart the products with antimicrobial property to prevent the microbial 
contamination (208). To reduce the toxicity of the QAS monomeric agent while 
keeping its antimicrobial efficacy and coating simplicity, we designed the novel 




containing monomer. The polymerization process is simple, potentially easy to scale 
up. At the same time, the coating process of the copolymers to a surface can remain 
the same to that of QAS monomeric agents, which doesn’t need elaborate techniques. 
The monomer used for PMT-5% and PMT-10% synthesis, MAPTAC is a 
commercial agent and was used as proof of concept for copolymer synthesis. On the 
other hand, DMA-C16Br is a customized monomer with a long 16-carbons long alkyl 
chain with an expectation to possess a better antimicrobial activity, since quaternary 
ammonium compounds were regarded to have the best antimicrobial activity with 
suitable long alkyl chains (C12-16) (219).   
The QAS polymer coatings were characterized by using ATR-FTIR and further 
confirmed by contact angle measurement. It was shown that the QAS copolymer 
coatings increased the hydrophobicity of the glass surfaces. PDT-10% and DTPAC 
coatings resulted in similar hydrophobicity of the glass surfaces, while PMT-5% and 
PMT-10% coatings showed an even higher hydrophobicity. The hydrophobicity of 
the PDT-10% coating may mainly result from reorientation of the long alkyl groups 
(tail) of the silane compounds, just like what was suggested for DTPAC coatings 
(220, 221). On the other hand, PMT-5% and PMT-10% copolymers increased the 
hydrophobicity of the coated surface even more, which may be due to the formation 
of the long alkyl chains of the synthesized polymers. 
Durability and non-leaching property are critical factors for antimicrobial coatings 
to provide long-lasting antimicrobial performance without toxicity concerns. 
Abrasion test showed that the QAS copolymer coatings became much more resistant 
to abrasion with TMSPMA containing siloxane linkages, which can anchor the 
substrate by covalent bonding other than physical attachment. The improved 




higher TMSPMA content which provided more “anchors” with the coated substrates. 
Considering this, PDT-10% was designed from DMA-C16Br together with 10% 
TMSPMA. Furthermore, the QAS copolymers also showed more resistant to 
abrasion than the QAS monomeric agent DTPAC. The retention of PDT-10% and 
DTPAC coating were further evaluated after 100 cycles of abrasion test, and it was 
shown that PDT-10% still had a retention of 62.0 ± 9.9%, while the peaks for 
DTPAC was not detectable. Actually, at the same concentration, DTPAC has a much 
greater amount of methoxysilane groups but non-specific siloxane bond formation 
may happen between DTPAC molecules instead of with the glass substrate. Thus, 
this in situ polymerization could cause most of the non-specific DTPAC polymers 
to be removed after abrasion test. On the other hand, the synthesized QAS 
copolymers possess long “fiber-like” structure that could possibly further cross-link 
with each other and formed a mesh network during the coating process. Then, the 
complex mesh network was subsequently grafted onto the substrate. Therefore, the 
formation of this complex mesh network could explain the enhanced resistance of 





Figure 4.11 Graphic illustration that the novel QAS antimicrobial copolymers (PMT-5%, 
PMT-10% and PDT-10%) exhibited improved biocompatibility as compared to the 
commercial antimicrobial QAS monomer (DTPAC). The copolymers can form transparent 
and durable coatings via a facile thermal-curing process. 
Crucial characteristics of polymers intended for the use as antimicrobial materials 
in household, industrial and clinical applications include not only the presence of 
antimicrobial activity but also the absence of toxicity to human cells. Differential 
cytotoxicity to microbial cells and human cells should invariably be addressed when 
evaluating of the QAS copolymers for future in vivo applications. LC50 values 
clearly showed that PMT-5% and PMT-10% were less toxic than PDT-10%, while 
PDT-10% was less toxic than the commercial QAS agent, DTPAC. The human cell 
toxicity of the QAS compounds were thus negatively correlated with their 
antimicrobial activity against S. aureus and C. albicans in solution, although the 
MIC values of these QAS compounds against E. coli were similar at 62.5 µg/ml. 
These findings suggest that our synthesized QAS copolymers are less toxic to human 
cells than the commercial QAS monomeric agent, DTPAC. So the synthesized QAS 




The MIC and MBC/MFC tests showed that the QAS copolymers are less effective 
than the commercial QAS monomeric agent, DTPAC, especially against fungus C. 
albicans. However, results from the MIC and MBC/MFC tests represent the QAS 
compounds’ antimicrobial activity in solution and are not direct indicative of their 
properties upon coating (184, 194). Hence, antimicrobial testing with the QAS 
copolymer treated surfaces were carried out. The results showed that antimicrobial 
efficacy of both QAS copolymer (PMT-5% and PMT-10%) coatings are as effective 
as that of QAS monomeric agent (DTPAC at 10 mg/ml) coating against S. aureus 
and E. coli. For a better comparison between PDT-10% and DTPAC, DTPAC 
coating was also carried out at the same coating solution concentration of 5 mg/ml 
as that of PDT-10% coating, but it lost the effectiveness against E. coli (log reduction 
less than 2) although the effectiveness against S. aureus remained. Furthermore, the 
antimicrobial result of QAS coatings against C. albicans was different from that of 
QAS solutions. DTPAC, the monomeric QAS agent was not effective against C. 
albicans upon coating although it was effective against C. albicans in solutions. 
More interestingly, the QAS copolymers were effective against C. albicans upon 
coating on glass surfaces, although PMT-5% and PMT-10% were ineffective against 
C. albicans and PDT-10% are less effective than DTPAC in solutions.  
Our results further confirmed previous observation that antimicrobial activity in 
solution are not direct indicative of their real property upon attachment to a surface 
(184, 194).  High surface concentration of antimicrobial groups (cationic quaternary 
ammonium groups)  may make surface-attached polymers bactericidal/fungicidal to 
microbes resistant to these polymers in solution (184). Although PMT-5% and 
PMT-10% do not possess the long alkyl chain as PDT-10% and DTPAC, a higher 




which may lead to higher resistance to bacteria adherence (221). Furthermore, the 
QAS copolymer coatings are supposed to have a higher mobility compared to 
monomeric QAS agent because of their long flexible alkyl backbone chain pendent 
with cationic quaternary ammonium groups, which may have impact on the 
antimicrobial activity as well. 
After antimicrobial experiment, the substrates were rinsed and dried, then subjected 
to ATR-FTIR testing again to check the durability of QAS coatings after bacterial 
challenge. The characteristic peak of copolymers still remained even though the 
coatings have experienced vigorous solution mixing and rinsing during the previous 
antimicrobial assays. It not only demonstrated strong adhesion of polymer coatings, 
but also the high stability of the polymer coatings. Ideally, the activity of these QAS 
coatings shall be permanent because their quaternary ammonium groups are not 
consumed during the biocidal process.  
The QAS copolymers are expected to be able to be coated on a large range of 
substrates and exhibit durable antimicrobial activities similar to other QAS 
monomeric compounds (222). The coating on glass serves as a proof of concept. 
Glass has many applications, including packing, windows, optical lenses and 
medical devices. Our studies have demonstrated the low toxicity of the QAS 
copolymer and the superior antimicrobial efficacy of QAS copolymer coatings on 
the glass surfaces, which are expected to provide a long-lasting effect in inhibiting 
microbial infection.  
4.5. Conclusion 
Novel antimicrobial QAS copolymers, namely, PMT-5%, PMT-10%, and PDT-10%, 




costly, rendering their production potentially feasible on the industrial scale. 
Cytotoxicity assays with HDF cells, HaCaT keratinocytes and HEK293 cell lines 
indicated that the QAS copolymers are less toxic to human than a commercial QAS 
monomeric antimicrobial agent. Moreover, QAS copolymers were capable of 
forming effective antimicrobial coatings against both bacteria (S. aureus and E. coli) 
and fungus (C. albicans) via a facile thermal-curing process. Abrasion resistant 
results showed that QAS copolymer coatings were more durable than a coating 
formed by DTPAC. The new QAS copolymers have a great potential to be used as 





Chapter 5 Fabrication of antimicrobial microneedles with a 
QAS copolymer coating 
5.1. Introduction 
Microneedle-based drug delivery systems are not equivalent to conventional transdermal 
patches, in that they are not simply applied to the surface of skin. Microneedles function 
principally by breaching the protective barrier of skin, the stratum corneum, and often 
penetrate into the viable epidermis and dermis (223). The stratum corneum can prevent the 
foreign materials, including microorganisms, from entering the body. As such, one of the 
most important factors limiting the clinical usage of microneedles is the risk of infection 
because of the compromised stratum corneum. Microneedle treatment was found to permit 
the permeation of bacteria by means of various in vitro models, including Silescol 
membranes, excised porcine skin and mouse skin, although the extent of the permeation 
was not greater than that enabled by hypodermic injection (87, 88). In addition, 
microorganisms were shown to adhere to microneedles after its application (87). Therefore, 
inappropriate reuse of microneedles will increase the risk of infection. Furthermore, 
clinical trials that demonstrated lack of infection with microneedle usage recruited healthy 
volunteers and prior to application of microneedle arrays, skin treatment sites were 
typically cleansed with alcohol wipes to reduce the skin’s microbial bioburden. However, 
the infection risk of microneedles in immunocompromised patients is unknown (89). As 
such, it is suggested that patient safety would be enhanced by manufacturing microneedles 
using sterile techniques. The risk of infection associated with microneedles use may also 
be reduced by imparting microneedles with antimicrobial properties. 
Some polymeric microneedles can have antimicrobial effect because of the material itself 




microneedles with thin films of antimicrobial materials. Gittard et al. reported a silver 
coated antimicrobial ceramic microneedles by using a physical vapour deposition 
technique. An agar plating method demonstrated the efficacy of the silver-coated 
microneedle array against S. aureus (225). However, this antimicrobial system is leachable, 
which may lose the antimicrobial activity gradually and cause environmental issues. 
Besides, bacteria resistance may be a problem as well, because silver’s broad-spectrum 
antimicrobial activity is attributed to the inhibition of DNA replication, expression of 
ribosomal and other cellular proteins, and disruption of the bacterial electron transport 
chain (226-229). Similarly, Gittard fabricated antimicrobial polymeric microneedles with 
silver and zinc oxide coatings, which were intended for the treatment of local skin 
infections (230). Microneedles coated or incorporated with other antimicrobial materials 
have also been reported but were designed for treatment purpose. For example, 
amphotericin B were coated on Gantrez® AN 169 microneedles by piezoelectric inkjet 
printing for the treatment of cutaneous fungal infections and cutaneous leishmaniosis (231). 
Antifungal pharmaceutical agent, voriconazole was loaded on polyglycolic acid 
microneedles by a similar coating method (232). Green tea extract was incorporated inside 
hyaluronic acid microneedles to reduce wound infection (233). 
In Chapter 4, we described the development of some novel QAS copolymers and 
demonstrated their antimicrobial effectiveness upon coating. These compounds contain the 
antimicrobial quarternary ammonium component and a methoxysilane group, capable of 
being immobilized on surfaces to form a durable coating. In this chapter, one of these QAS 
copolymers, PDT-10% was used to form a permanent antimicrobial coating on 3M MSS. 
3M MSS is provided in a sterile state, but it is accessible by end users for home usage. So 
reuse is quite possible on uncleansed skin. The antimicrobial coating is not designed for 




and in the case of inappropriate microneedle reuse. We hypothesize that PDT-10% can be 
successfully coated on the microneedles and the coating is effective, durable and safe. 
5.2. Materials and Methods 
5.2.1. Materials 
PDT-10% was synthesized in house referring to Chapter 5. Isopropanol is purchased from 
Tedia, USA. Acetic acid is purchased from Merck, USA. Rhodamine B was purchased 
from Alfa Aesar, UK. The source of materials for antimicrobial test and cell culture were 
the same with that used in Chapter 5. 
5.2.2. Preparation of PDT-10% coated microneedles 
5 mg/ml of PDT-10% coating solution was solubilized in a mixture containing 90% of 
isopropanol and 10% of acetic acid solution (pH 2.5) following by heating at 50 ˚C for 30 
min. Before coating, 3M MSS microneedle array was primed with oxygen plasma in a 
plasma cleaner for 3 min to render them hydrophilic. Then 90 µl of the PDT-10% coating 
solution was transferred to the treated microneedle array and the array was heated at 50 °C 
for 1 h to ensure the coating of PDT-10% on the needles. The coated needles were washed 
under tap water for 10 seconds, and the washing was repeated for 5 times with 10 seconds’ 
interval between each washing before drying again in oven. 1 mg/ml and 0.2 mg/ml of 
PDT-10% coating solution was further prepared and was used to coat 3M MSS for 
antimicrobial and cytotoxicity test. 
5.2.3. Characterization of PDT-10% coating on microneedles 
SEM was applied to analyze the microneedle morphology change after coating followed 




applied to coat the samples at 10 mA for 180 s. The analysis was performed on FE-SEM 
(JSM-6700F, JEOL, Japan) equipped with Oxford Instruments INCA X-ran microanalysis 
system (EDS).  
Rhodamine B staining method was used as an indirect method to characterize the change 
of microneedle surface property after PDT-10% coating.  The coated microneedle array 
was flood-stained with 90 µl of 1 mg/ml rhodamine B solution and dried at 50 °C for 1 h, 
then the microneedles were observed under a stereomicroscope. To exclude that coating 
solvent of PDT-10% will not change the microneedle properties, microneedle arrays that 
experienced plasma treatment and flood-coating of a mixture containing 90% of 
isopropanol and 10% of pH 2.5 acetic acid solution were used as negative control.  
ATR-FTIR was used to monitor the crosslinking reaction between the microneedle array 
and PDT-10%.  The back of the microneedle array has a flat surface and was used for this 
characterization. The back of the microneedle array was coated with PDT-10% in the same 
way as described above for microneedles and then subjected to ATR-FTIR examination. 
Infrared spectra were collected between 4000 and 650 cm-1 at a resolution of 4 cm-1. 
5.2.4. Durability of PDT-10% coating on microneedles 
In order to evaluate the durability of PDT-10% coating on microneedles, the coated 
microneedles were applied on human dermatomed skin at a force of 22.2 N for 20 times, 
then the microneedles were subjected to rhodamine B staining for characterization.  
5.2.5. Antimicrobial assays of QAS copolymers and coatings 
S. aureus was grown to their exponential phase and appropriately diluted in 0.3% agar 
slurry to achieve the standard inoculum size around 4 – 7 × 106 CFU/ml. The agar slurry 




bacterial agar slurry was added on the PDT-10% coated microneedles and spread with 
pipette tips to ensure the good contact. Uncoated microneedles were used as controls. 
Bacteria recovery was carried out after incubation at 37 °C in humidified condition for 24 
hours. Inoculated bacteria were recovered by placing the tested microneedles into 50 ml 
Falcon tubes containing 10 ml of PBS with 0.5% Tween 80. The tubes were sonicated for 
1 min in an ultrasonic water bath (Ultrasonic LC60H, Fisher Scientific) and then vortexed 
for 1 min before serially diluting the samples in the Tween 80 containing PBS. A viable 
count was conducted using the spread plate method after appropriate dilution. The CFUs 
were counted and the antimicrobial activity was expressed as log reduction number of the 
microorganisms after 24 hours compared with control. If no colony was found on the plate 
even at the lowest dilution time, then the count was taken as one for calculation. 
5.2.6. Cytotoxicity assay  
The biocompatibility of the coated microneedles was evaluated by testing their cytotoxicity 
against HDF and HaCaT keratinocytes using MTT assay.  Microneedles coated with 
different concentrations of PDT-10% were extracted in 3 ml of PBS at 37 °C for 24 hours.  
Cells were seeded at a density of 104 cells per well in 96-well flat-bottomed microplates 
(Costar, Corning) and incubated with DMEM culture medium (supplemented with 10% 
FBS and 1% penicillin-streptomycin solution) for 24 hours. Thereafter, the culture medium 
was replaced with 180 µl of fresh medium and 20 µl of microneedle extraction solution in 
each well. For control group, 180 μl fresh culture medium and 20 μl of PBS were added. 
The culture medium was removed after 24 hours of incubation. Then 20 µl of fresh medium 
and 20 µl of sterile MTT solution (5 mg/ml in PBS) were further added. After another 4 
hours of incubation at 37 °C, the supernatant was removed by aspiration, and resultant 




nm was measured using a microplate reader (Tecan, Switzerland) with 650 nm as reference 
wavelength. Relative cell viability was represented as the percentage of the control group.  
5.3. Results 
5.3.1. Preparation and characterization of microneedles coated with PDT-10% 
Figure 5.1 showed that the contact angle of microneedle back surface was reduced from 
around 78° to 20° after plasma treatment, which means that plasma treatment rendered the 
surface more hydrophilic. The plasma activated microneedles were further coated with 
PDT-10%. 
 
Figure 5.1 Contact angles of the back surface of microneedle array. (A) Untreated surface. 
(B) After plasma treated for 3 min. 
We further evaluated how long this effect would last. Figure 5.2 indicates that the contact 
angle only increased with time slightly after plasma treatment. This ensured enough 





Figure 5.2 Change of contact angle with time after plasma treatment. 
The appearance of the PDT-10% coated microneedles remained the same white colour as 
control and no difference was observed under stereomicroscopy (up to 12.25 times 
magnification) compared with control microneedles. By using SEM, a high magnification 
of microneedles was shown. It was shown in Figure 5.3 that the surface of PDT-10% 
coated microneedles was rougher than the control microneedle. The change of surface 
property may be mainly due to the PDT-10% coating. The EDS analysis demonstrated the 
existence of bromine atom on the coated microneedles, which further confirmed the 





Figure 5.3  SEM/EDS analysis. (A) Control microneedles. (B) Microneedles coated with 
PDT-10%. 
Rhodamine B staining method was used as an alternative method to characterize the change 
of surface property of microneedles after PDT-10% coating. Figure 5.4A showed that 
rhodamine B only accumulated at the base of the needles and did not stain on the tips of 
control needles. On the other hand, the whole needle body was stained with rhodamine B 
on PDT-10% coated microneedles (Figure 5.4B), which indicated that the tips of 
microneedles were successfully coated with PDT-10% by the flood coating method. After 
20 times of penetration test on skin, the PDT-10% coated microneedles were well stained 
by rhodamine B as well (Figure 5.4C). This indicated that the PDT-10% coating was not 





Figure 5.4  Characterization of microneedle surface by rhodamine B coating method. (A) 
Negative control microneedles. (B) PDT-10% coated microneedles. (C) PDT-10% coated 
microneedles after 20 times of penetration test on skin. Scale bars represent 500 µm. 
ATR-FTIR demonstrated that the coating of PDT-10% on microneedles was not physical 
deposition, but by forming chemical bonds (Figure 5.5).  PDT-10% has a strong peak at 
1089 cm-1 which is the characteristic stretch of the Si─O bond of methoxysilane (–Si-O-
CH3). The formation of siloxane crosslink during the coating process was confirmed by the 
disappearance of the 1089 cm-1 peak after coating, because methoxysilane group was 
subjected to hydrolysis and formation of siloxane crosslink during the coating process. The 
ATR-FTIR also showed that the PDT-10% was not washed away as indicated by the 
similar profiles before and after washing. 
 




5.3.2. Antimicrobial test 
As shown in Figure 5.6, the antimicrobial efficacy of the PDT-10% coated microneedles 
depended on the concentration of the PDT-10% coating solution and varied against 
different microbial species. It was shown that microneedles coated with 5 mg/ml and 1 
mg/ml of PDT-10% displayed excellent antimicrobial activity against S. aureus and C. 
albicans with log reduction more than 2. The antimicrobial activity against E. coli was less 
effective than that against S. aureus and C. albicans, with log reduction at 1 when 
microneedles were coated with 5 mg/ml of PDT-10%.  
 
Figure 5.6 Viable bacterial counts of PDT-10% coated microneedles (MN) against S. 
aureus, E. coli and C. albicans after 24 hours of exposure (A) and the corresponding 




5.3.3. Cytotoxicity test 
After incubation with the extract of PDT-10% coated microneedles for 1 day, no significant 
difference in cell viability was observed as compared to controls (Figure 5.7). It indicated 
that PDT-10% coated microneedles were not toxic to either HaCaT keratinocytes or HDF 
cells.  
 
Figure 5.7 Relative human cell viability after 24 hours of exposure to the extract of PDT-
10% coated microneedles (MN) 
5.4. Discussion 
Quaternary ammonium silane compounds have been used for a long time by offering 
a surface protection method without addition of chemicals to the environment (222). 
Our synthesized QAS copolymers demonstrated a lower toxicity as well as superior 
and durable antimicrobial activity upon coated on glass surface (234). PDT-10% 
showed a superior antimicrobial activity among these QAS copolymers and it was 
further proposed to confer the microneedles (3M MSS) with antimicrobial activity. 
3M MSS is injection molded from liquid crystal polymers (LCP) due to their 




chemical stability and good biocompatibility (235). However, the low surface 
energy of the LCP polymer and the resulting poor adhesion of additional coatings 
make it difficult to be coated. On the other hand, low pressure and low temperature 
non-equilibrium plasma activation is a suitable method for pre-treating the surface 
of many polymers. The excited species of the plasma can modify most polymer 
surfaces to a depth of several nanometers to achieve  desired polarities while 
maintaining the bulk properties, regardless of their substrate pattern geometry and 
chemical reactivity (236).  
It was observed that the plasma treatment lowered the contact angle of the 
microneedle back surface. This is because the plasma can activate the polymer 
surface to generate more oxygen-containing functional groups (such as –OH and –
OOH) on the polymer surface thus increasing the hydrophilicity of the surface (237). 
The same reactive functional groups are expected to exist on the needle surface after 
plasma treatment, which can then form crosslink with the silane group of PDT-10%. 
The crosslink process was confirmed by FTIR characterization. SEM and indirect 
rhodamine B characterization further indicated the change of the microneedle 
surface properties after PDT-10% coating.  Besides, the PDT-10% coating was 
durable as indicated by 20 times of penetration test. 
As expected, antimicrobial activity of PDT-10% coated microneedles was 
dependent on the concentration of coating solution and varied against different 
microbial species. It was demonstrated that PDT-10% coated microneedles were 
effective against S. aureus and C. albicans with log reduction values of more than 2 
at the coating concentration of 5 mg/ml and 1 mg/ml, while significant reduction of 
bacteria number was also observed against E. coli at the same coating concentration. 




solution are not direct indicative of their real property upon attachment to a surface and the 
antimicrobial activity varied when coating on different surfaces (184, 194). Currently, 
only a few papers were published on antimicrobial microneedle fabrication. Gittard 
et al. demonstrated the antimicrobial efficacy of a silver coated microneedles by agar 
diffusion method  (225). This method is not suitable to test our non-leachable antimicrobial 
system. Other antimicrobial microneedles were designed to delivery antimicrobial 
substances for treatment purpose, which is different from our antimicrobial micorneedles 
(230-233).  
Cytotoxic assay further demonstrated that these antimicrobial coating was not toxic 
to human cell lines and indicated that they may be safe to human body. 
In summary, this study demonstrated a method to confer microneedles with effective 
antimicrobial activity against S. aureus, E. coli, C. albicans with a QAS copolymer 
coating by a simple thermal-curing process. S. aureu, E. coli and C. albicans are 
commonly existing bacteria on skin. Other skin pathogens, such as Streptococcus 
pyogenes, Staphylococcus epidermidis may also be tested (238). Furthermore, the 
plasma treatment method changed the surface property of the microneedles and 
rendered the coating possible. This plasma pretreatment method can potentially be 
used to coat other drug molecules on microneedles as well. A recent study also 
indicated that plasma treatment significantly increased the surface energy and 
roughness of the polycarbonate and polyether ether ketone microneedles resulting 
in better adsorption and release of BSA (239). The flood coating method used in our 
study seems suitable for characterization or the antimicrobial coating, but it may not 
be suitable for a quantitative drug coating. Other quantitative coating method may 
be employed for drug coating purpose. Furthermore, PDT-10% is expected to be coated 




microneedles made from other materials can also be tested with PDT-10% coating to 
harvest the antimicrobial activity to reduce the risk of infection. 
5.5. Conclusion 
Microneedles with durable and effective antimicrobial properties were developed by 
coating the microneedles with a QAS copolymer, PDT-10% after plasma treatment. 
Biocompatibility of the coating was demonstrated by in vitro cytotoxicity assay. The 
antimicrobial coating can potentially be applied on microneedles made from other 





Chapter 6 Development of lidocaine HCl dry patch with 
microneedle pretreatment for fast anesthetic effect 
6.1. Introduction 
Pretreatment of skin by microneedles following with a drug-loaded topical formulation is 
one of the frequently studied microneedle-assisted drug delivery systems. However, the 
influence of drug formulation on drug diffusion through the microneedle pretreated skin is 
not thoroughly investigated. Since the stratum corneum is bypassed by microneedles, the 
current formulations for passive transdermal drug delivery may not be suitable for 
microneedle assisted transdermal drug delivery. In this chapter, we investigated the 
development of percutaneous lidocaine delivery with microneedle pretreatment. 
Various formulations have been developed for skin application of lidocaine on intact skin, 
including liquid, cream, gel, patches, etc. Creams and gels have a higher drug loading on 
skin than liquid, but the doses are variable and contamination of hands happens, which are 
the same issues associated with liquid formulation. Considering these issues, patches are 
more preferable although they are more expensive. Furthermore, with an occlusion by a 
backing layer, higher drug absorption is expected with patches used on skin. Among 
different types of transdermal patches, the drug-in-adhesive system, in which the drug is 
incorporated in the adhesive layer contacting skin, is very commonly used (240).  When 
developing a drug-in-adhesive system, the adhesive should be compatible with drug and 
excipients, including the solubility of drug and excipients in adhesive, effect of 
dissolved/dispersed additives on mechanical properties of adhesive, and long-term stability 
of dissolved/dispersed components (241). In order to increase the thermodynamic activity 
hence the skin permeation, saturated drug is usually used in adhesive matrix. However, 




decrease delivery rate but also decrease the adhesion of the patch (242). On the other hand, 
only a small portion of drug was effectively absorbed by skin despite the high drug loading. 
For example, for a commercial lidocaine patch, Lidoderm®, only less than 5% of the dose 
applied is expected to be absorbed. At least 95% of the drug remains in an used patch, 
which is a potential risk for a child or a pet to suffer serious adverse effects from chewing 
or ingesting the used patch (243). Furthermore, in order for a drug to be successfully 
absorbed, the drug has to release from the adhesive matrix system to the skin surface, then 
diffuse through the stratum corneum, which is considered as the main barrier for 
percutaneous drug delivery. The passive drug diffusion process results in a delay between 
the patch application and the development of a desired minimum effective concentration, 
which is called lag time. For example, the commercial lidocaine formulations, including 
EMLA® cream, EMLA® patch and Lidoderm patch take 60 min to 4 h to produce analgesia 
(243, 244).  Therefore, there is a need for a further development of percutaneous lidocaine 
delivery system, including effective usage of drug and a decrease in lag time. On the other 
hand, it was found that microneedles can not only enhance the skin permeation but also 
decrease the onset time of drug effect by bypassing the stratum corneum (35, 53, 139). 
However, just as discussed above, the current lidocaine formulations may not be suitable 
for the drug delivery with microneedle assistance because the stratum corneum is breached 
and microchannels are created. Furthermore, the adhesive and excipients of existing patch 
may cause skin irritation issues along with the enhanced permeability in the breached skin. 
To minimize the potential risk of a microneedle assisted drug system, less excipients should 
be used in the patch system. 
In this study, we hypothesized that microneedles would create an alternative route for drug 
permeation though skin and it should have a preference of drug molecules based on their 




was compared with microneedle pretreatment. Furthermore, the drugs were fabricated into 
an adhesive and solvent free patch, named “dry patch” by spraying coating with limited 
excipient incorporated inside. The resulted single layer patch allowed drug release without 
the hindrance of a matrix thus allowed the effective usage of drug. Both in vitro 
permeability study on human skin and in vivo study on pig skin were conducted to evaluate 
the efficacy of the new delivery systems with or without microneedle pretreatment. This 
study would provide future strategies for the reasonable design of a microneedle assisted 
drug delivery system.  
6.2. Materials and methods 
6.2.1. Materials 
Lidocaine was purchased from TCI, Japan. Lidocaine hydrochloride monohydrate, 
polyvinylpyrrolidone, sucrose, prilocaine, proteinase K, ammonium hydroxide, Na2HPO4, 
PBS, 10% Neutral Buffered Formalin were purchased from Sigma-Aldrich, Singapore. 
HPLC-grade isopropyl alcohol and acetonitrile were supplied by Tedia, USA. The 
commercial patch, Lidoderm® (lidocaine patch 5%), is a product of Endo Pharmaceuticals. 
Water used in the paper was purified using Millipore Direct-Q.  
6.2.2. Fabrication of lidocaine and lidocaine HCl dry patch 
10 mg/ml lidocaine and lidocaine HCl were dissolved in 80% ethanol water solution 
respectively with 6.7 mg/ml polyvinylpyrrolidone and 3.3 mg/ml sucrose added. The 
solution was then transferred into the container of a spray machine (Spray Master ME-
5000SP, Musashi, Japan). The movement of spray valve was controlled by a desktop robot 
(SHOTMASTER 300, Musashi, Japan) within an area of 10 cm by 10 cm on a polyethylene 




dried at 130 °C for 1 min. After cooling down, the coated film was laminated with a release 
liner (Scotchpak® 9744, 3M). The resulted Lidocaine and Lidocaine HCl patches were 
named as lidocaine dry patch and lidocaine HCl dry patch, respectively. The fabrication 
process of dry patches was illustrated in Figure 6.1. 
For the content assay, the dry patch was cut into 5 cm2 by a metal punch and the drug was 
recovered by shaking in 5 ml of 80% ethanol water solution for 3 h at 200 rpm, followed 
by HPLC analysis. 
 
Figure 6.1 Illustration of the fabrication process of “dry patch”. 
6.2.3. Characterization of dry patches by microscopy methods 
The thickness of the dry patches and Lidoderm patch was compared under a stereoscopic 
microscope by taking the cross section images (Nikon SMZ25, Japan). Furthermore, a 




then attached to a stub by a carbon tape (NEM tape, Nisshin EM. Co. Ltd.), and platinum 
sputter-coated using a JFC-1600 autofine coater (JeOL, Japan) at a current of 10 mA for 
80 s. The cross section images of the dry patch were then taken using a JSM-6700F FE-
SEM (JEOL, Japan) followed by energy dispersive X-ray spectrometer (EDS) 
characterization. 
6.2.4. Characterization of the release liner after removal from dry patches 
The release liner was examined for residue drug after removal from the dry patches by 
using a Spectrum 100 Fourier transform infrared (FTIR) Spectrophotometer (PerkinElmer, 
USA) with an attenuated total reflectance (ATR) set-up. Lidocaine or lidocaine HCl was 
used as positive control while a blank release liner as negative control.  Infrared spectra 
were collected between 4000 and 650 cm-1 at a resolution of 4 cm-1. 
6.2.5. In vitro release study  
Drug release from lidocaine and lidocaine HCl dry patches was compared with that from 
the commercial patch, Lidoderm using Franz diffusion cells. A cellulose nitrate membrane 
was placed between the donor compartment and the receptor compartment. A patch with 1 
cm2 was pressed on the membrane. The receptor compartment contained 4.8 ml of PBS 
solution. The cells were placed inside a chamber with temperature controlled at 32 °C, and 
there was a magnetic stirrer in the receptor cell with a stirring speed of 100 rpm. The 
receptor solutions were withdrawn at pre-set time intervals and replaced with fresh ones. 
Three replicates were conducted for each group. Lidocaine concentration in receptor 




6.2.6. In vitro skin permeation study  
Franz diffusion cells were also used in in vitro skin permeation study to evaluate the 
performance of different lidocaine formulations with or without microneedle treatment. 
Different from release study, human dermatomed skin was used between the two 
compartments instead of a membrane. The back skin of a 66-year-old Caucasian female 
cadaver was used in the experiment and the skin was obtained from Science Care (Phoenix, 
AZ, USA). The skin was spread over a 6 mm thick PDMS substrate mounted on a 
Styrofoam board with epidermis side up. A microneedle array was then pressed on the skin 
sample with a force of 22.2 N for 10 seconds, which was controlled by using a force gauge 
(HF-10, JISC, Japan).  
Either intact skin or microneedle pre-treated skin was mounted onto Franz diffusion cells 
with epidermis facing up. Lidocaine and lidocaine HCl solution (both equivalent to 5% 
lidocaine), lidocaine and lidocaine HCl dry patches, together with the commercial patch 
Lidoderm, were evaluated by putting 0.5 ml solution in the donor compartment or pressing 
a 1cm2 patch on the skin. The receptor compartment contained 4.8 ml of PBS solution. The 
cells were placed inside a chamber with temperature controlled at 32 °C, and there were 
magnetic stirrers in the receptor cells with a stirring speed of 100 rpm. The receptor 
solutions were withdrawn at pre-set time intervals and replaced with fresh ones. Three 
replicates were conducted for each group. Lidocaine concentration in receptor solutions 
were analyzed by HPLC. The use of human cadaver skin was approved by the National 
University of Singapore Institutional Review Board. 
6.2.7. In vivo pig study 
Young adult female pig (Yorkshire X, Holland), weighing 25-40 kg were used for the study. 




isoflurane gas followed by administration of Atropine to reduce salivary, tracheobronchial 
and pharyngeal secretions. While the animal was under anesthesia, hair and dirt on the 
swine skin at the intended application sites were removed. Subsequently, the hair was first 
clipped using an electric shaver followed by a wet disposable razor and patted dry. Four 
replicates were conducted for each group. 
The microneedle array (3M MSS) were applied on the skin with a hand force of around 20 
N (estimated by using the force gauge) for 10 s. Then a lidocaine dry patch or lidocaine 
HCl dry patch or Lidoderm patch (0.5 cm × 1 cm) was pressed on the microneedle treated 
area immediately after microneedle removal. The dry patch was fixed on the skin with a 
medical tape (Smith & Nephew, Germany). The commercial patch, Lidoderm was used as 
a bench mark. Intact skin without microneedle treatment was used as control.  
At predetermined time points (10 min, 30 min, 1 h, 2 h, 4 h, 6 h and 8 h), patches were 
removed. Then the skin was cleaned three times with a cotton swab using PBS followed 
by drying with dry cotton swab. Thereafter, skin biopsies were collected by using sterile 
biopsy punches (Miltex USA, 4mm) from the center of the patch application site. The 
weight of skin biopsies were determined by weighing the tube with and without biopsies. 
The drug concentration in the skin biopsies were analyzed by liquid chromatography–mass 
spectrometry (LC-MS). All animal testing procedures were approved by the Institutional 
Animal Care and Use Committee, National University of Singapore.  
6.2.8. HPLC to determine dry patch lidocaine loading and lidocaine concentration 
in in vitro release / skin permeation study 
Lidocaine concentration was determined with a reversed phase HPLC (Agilent 1200, US) 
using a Zorbax Extended-C18 Rapid Resolution HT column (1.8 µm, 2.1 mm × 50mm, 




acetonitrile in an isocratic mode at a flow rate of 0.4 ml/min. The ultraviolet detection 
wavelength is set at 230 nm. The standard concentration ranged from 0.1 µg/ml to 100 
µg/ml. 
6.2.9. LC/MS/MS to determination lidocaine concentration in skin biopsies  
Skin biopsies were first digested by Proteinase K (75 µg/ml, 150µl) at 55 °C for 6 h.  Then 
three parts of methanol (containing prilocaine as internal standard) were added into the 
homogenous digestion mixture to precipitate protein by votex mixing for 5 min followed 
by centrifugation at 14,000 ×g for 20 min at 4 °C. Supernatant obtained was quantitatively 
analyzed by Agilent 1200 series LC/MS/MS system, comprised of capillary pump, 
autosampler, and triple quadrupole mass detector (Agilent 6400 series). Data were acquired 
and processed using Mass hunter workstation software version B.02.01.  The samples were 
analyzed using electrospray ionization in positive ion mode with Turbo Ion Spray interface. 
Operating conditions optimized by Mass Hunter optimizer for Lidocaine and IS-prilocaine 
were: dry gas temperature at 350 °C, nebulizer pressure at 35 psi, nitrogen gas flow rate at 
12 ml/min; capillary voltage at 4000 V and fragmentor voltage at 90 V. Product ions (of 
lidocaine) resulting from transition of 235.2→86.1 (collision energy 16 V) and product 
ions (of prilocaine) 221.2→86 (collision energy 8 V) were monitored at retention time of 
3.1 min (for lidocaine) and 2.4 min (for prilocaine as internal standard). A Zorbax 
extended-C18 column (3.5µm, 4.6×75mm, Agilent) was used for the separation. The 
mobile phase was made of 50% of 25 mM ammonium hydroxide and 50% of isopropyl 
alcohol with methanol (1:1) mixture. The flow rate controlled at 0.5 ml/min. Calibration 
curve was plotted over the concentration range of 1-10000 ng/ml by running the standard 





6.3.1. Characterization of dry patches 
The drug content of lidocaine and lidocaine HCl dry patches are 111.6 ± 44.0 µg/cm2 and 
122.0 ± 8.9 µg/cm2, respectively. Compared to the commercial patch (with a drug content 
of 5000 µg/cm2), the drug loading of dry patches is 40 times less (Figure 6.2A). The dry 
patch consists a backing film with a thin layer of drug coating and a release liner layer. 
Without hydrogel or adhesive as drug vehicle in between, the dry patch with a thickness 
around 100 µm was much thinner than the commercial patch, Lidoderm (Figure 6.2B). 
SEM images indicated the thin layer of drug coating around 1 µm between the backing 
film and release liner (Figure 6.2C). The drug coating was further confirmed by elemental 
analysis, since the chlorine atom in the EDS graph (indicated by the red arrow) was due to 






Figure 6.2 Dry patch information. (A) Patch content information. (B) Phase contrast image 
of the cross section of a Lidocaine HCl dry patch (left) with contrast to Lidoderm patch 
(right). (C) SEM image of the cross section of Lidocaine HCl dry patch with its enlarged 
view of the drug layer on the right and the EDS result below.  
Since the drug in the dry patch is not trapped in hydrogel or adhesive, there is one concern 
that the drug may stick to the release liner during the liner removal. We used IR 
spectroscope to characterize the existence of the dry film after the liner removal. Figure 
6.3 shows that the spectrum of control liner and liner removed from the drug formulated 






Figure 6.3 ATR-FTIR to examine the existence of drug on liner after removed from 
Lidocaine HCl dry patch (A) and Lidocaine dry patch (B). 
6.3.2. In vitro release study  
Drug release from lidocaine and lidocaine HCl dry patches was compared with that from 
the commercial patch, Lidoderm using Franz diffusion cells. A cellulose nitrate membrane 
was placed between the donor compartment and the receptor compartment. A patch with 1 
cm2 was pressed on the membrane. The receptor compartment contained 4.8 ml of PBS 
solution. The cells were placed inside a chamber with temperature controlled at 32 °C, and 
there was a magnetic stirrer in the receptor cell with a stirring speed of 100 rpm. The 




Three replicates were conducted for each group. Lidocaine concentration in receptor 
solutions were analyzed by HPLC. 
Compared to the commercial patch which has a controlled release over time, the dry 
patches had an initial burst of release and almost no more drug was collected after 1 hour 
(Figure 6.4). Although the absolute cumulative release amount from the commercial patch 
is higher than dry patches, less than 15% of drug was release from the commercial patch 
at the end of 6 hours, while the corresponding percentage release for lidocaine HCl dry 
patch and lidocaine dry patch were 86.5% and 56.4%, respectively.   
 
Figure 6.4 Drug release from different patches. (A) Cumulative release amount. (B) 




6.3.3. In vitro skin permeation study 
Figure 6.5 showed the lidocaine permeation profile of the base form and salt form through 
human skin either with or without microneedle pretreatment. No matter in solution or 
formulated in patch, lidocaine HCl had a low permeability through intact skin, while 
lidocaine, the base form was much more effectively delivered through skin than the salt 
form when applied on intact skin. When the skin was pretreated with microneedles, there 
was a significant increase in the delivery of lidocaine HCl across skin by 83.3 times. 
However, microneedle pretreatment showed no enhancement effect on the skin permeation 
of lidocaine solution from the permeation profile graphs. Although the cumulative amount 
of lidocaine delivery for lidocaine HCl solution across microneedle treated skin was not 
significant higher than that for lidocaine solution on intact skin, the former group showed 
a first order release profile (r2 = 0.9981) and had a much steady flux over time. When the 
drugs were formulated into patches, including the commercial patch and dry patch, 
microneedles were found to have similar effect with that when drugs were in solution. 
When the skin was pretreated with microneedles, there was a significant increase in the 
drug permeation from lidocaine HCl dry patch across skin by around 9 times. But 
microneedles showed much less enhancement on the drug permeation from the lidocaine 
patches. More specifically, the drug permeation curves from the commercial patch were 
almost overlapped regardless the skin was microneedle pretreated or not. On the other hand, 





Figure 6.5 In vitro skin permeation test to study the effect of microneedle (MN) 
pretreatment on lidocaine skin transport with base form and hydrochloride form used. (A) 
When the drugs were in solution. (B) When the drugs were formulated into patches. 
6.3.4. In vivo study on pigs 
Figure 6.6 showed the skin lidocaine concentration after 6 hours’ application of different 
patches with or without microneedles treatment on pigs. It was found that lidocaine dry 
patch generally resulted in a higher lidocaine concentration than lidocaine HCl dry patch, 
but lower than the commercial patch when the patches were applied on intact pig skin. 
Considering the commercial patch, Lidoderm may have one-hour delay in anaesthesia 
effect, the resulted skin lidocaine concentration at 1 h was set as therapeutic level (243, 
244). When the pig skin was treated with microneedles, lidocaine HCl dry patch resulted 
in a lidocaine concentration higher than the therapeutic level as early as 10 min and the 
skin lidocaine concentration was steadier over time than that with the commercial patch. 
Microneedles also promoted Lidocaine dry patch performance by enhancing the skin 
lidocaine concentration. However, the commercial patch with microneedle pretreatment 





Figure 6.6 In vivo study on pigs to measure the skin lidocaine concentration when different 
patches were used with or without microneedles (MN). 
6.4. Discussion 
From in vitro skin permeation study when drug solutions were tested, it was observed that 
lidocaine was much more effectively delivered through skin than its hydrochloride salt 
when applied on intact skin.  This is because the intact skin is much more permeable to 
lipophilic drug (lidocaine, log P = 2.63) than hydrophilic drug (lidocaine HCl, log P ≤ 0), 
as suggested by previous paper that the lipid bilayers in the stratum corneum is the main 
pathway for percutaneous absorption (245). After human skin was pretreated with 
microneedles, the amount of lidocaine HCl permeated though skin increased more than 80 
times. Under passive diffusion in intact skin, the hydrophilic drug molecule, lidocaine HCl, 
had difficulty in permeating the lipid-based stratum corneum. However, when lipid barrier 
was overcome by microneedles with microchannels created, significant increase in the drug 
permeation was observed, which supports the fact that alternate route of permeation exists 
with the pretreatment of microneedle. This is consistent with previous report that 




delivery of hydrophilic molecules through the skin (83). A decreased lag time further 
ascertained the presence of an alternative permeation pathway. But microneedles had 
limited effect on lidocaine base delivery. It indicated that the permeation pathway of 
lidocaine remained the same even when micro-channels were created in the stratum 
corneum. Lidocaine did not utilize the aqueous pathway created by microneedles in the 
skin, probably because of its low aqueous solubility. 
Lidocaine and Lidocaine HCl were further formulated into dry patch by spray coating to 
be screened for a microneedle assisted system. Because of the high resistance in skin 
absorption process, a very high amount of drug is usually used in a thick conventional drug-
in-adhesive patch to ensure the effectiveness of patch although only a small portion is 
absorbed by skin. On the contrary, the dry patch described here is much thinner and more 
than 40 times less drug was loaded yet the effectiveness can be maintained. A thin patch 
or film can also be potentially applied buccal or sublingual besides transdermal (246). 
Furthermore, we don’t have to consider the drug adhesive compatibility and thus a variety 
of drug molecules can be adopted in the dry patch system. The spray coating itself is also 
a very easy and cost-effective process. The resulted “dry patch” is solvent and adhesive 
free, thus a better long-term stability during storage is expected (242). In pharmaceutical 
industry, spray coating has been widely used in the coating process of granular solids and 
tablets with coatings of the millimeter thicknesses (247). It was also proposed to coat the 
surface of microneedle arrays and other medical devices (248, 249). However, application 
of spray coating in transdermal patches/films has not been reported to our knowledge.   
Initially we had the concern that the dry state of drug in the spray coated dry patches may 
have difficulty in skin permeation, since drug have to be dissolved to a thermodynamic 
state and then utilize a certain pathway in the stratum corneum. Furthermore, the release 




the lower amount of drug was released from dry patches than that from commercial patch 
(Figure 6.4). Surprisingly in in vitro skin permeation study, lidocaine dry patch showed an 
even higher permeability than the commercial patch although 40 times less drug was loaded 
in the dry patch. After 6 hours, around 50% of drug in lidocaine dry patch permeated 
through skin.  It indicated that water in the skin itself was enough for hydrating the patch 
and dissolving drug after occlusion of dry patch on skin. On the other hand, the drug had 
to be released from the adhesive matrix of commercial patch before reaching the skin 
surface, while the thin layer of drug on dry patch seemed more easily accessible to skin 
surface without the hindrance of vehicle matrix under limited skin hydration condition. On 
the other hand, even when drugs were formulated into patches, microneedles showed its 
preference in increasing the skin permeation of hydrophilic drug, lidocaine HCl. 
Dermal pharmacokinetics of lidocaine was measured by biopsy analysis as reported (27). 
As expected, although lidocaine HCl dry patch resulted in a low skin concentration on 
intact skin in vivo, lidocaine HCl dry patch with microneedle assistance led to a skin 
concentration higher than therapeutic level in 10 min. Besides, a steady effective skin 
concentration with time up to 6 hours was obtained with the microneedle plus lidocaine 
HCl dry patch application. This is different from previous reports where only a short term 
effect was obtained with lidocaine coated microneedles or microneedle pretreatment plus 
lidocaine injection application (27, 28). The result demonstrated that the lidocaine HCl dry 
patch can resulted in an effective skin lidocaine concentration over 6 hours yet with a much 
faster onset of effect with the assistance of microneedles, although drug loading in 
lidocaine HCl dry patch was 40 times less than the commercial patch.  
Our study demonstrated that lidocaine HCl was preferred in a microneedle assisted system, 
which is different from the drug selection standard for a conventional percutaneous drug 




effect in vivo with microneedle assistance. It overcame the limitations of conventional 
drug-in-adhesive patch, such as complicated patch design, waste of drug, and delayed drug 
effect. This preliminary study demonstrated the possibility of spray coated dry patch as a 
delivery vehicle used together with microneedle pretreatment. In future study, long term 
stability of the dry patches system needs to be further investigated. In order to be applied 
on skin conveniently, the patch was proposed to have a peripheral layer of adhesive. 
Current in vivo study only demonstrated 6 hours’ effectiveness, and there is one concern 
that the current dry patch may not support an effectiveness for a longer time because of the 
low drug loading. Nevertheless, the spray coating process is quite flexible, the drug loading 
may be increased by using a higher concentration of spraying solution or multiple layers 
of coating. Furthermore, the dry patch plus microneedle pretreatment system is a two-step 
method. A simplified way is possible by incorporating the thin patch with a microneedle 
applicator device with a patch housing compartment, then the patch can be dispensed for 
application to a target site automatically after microneedle application (250). 
6.5. Conclusion 
In this study, it was demonstrated that the hydrophilic lidocaine HCl molecule is preferred 
in a microneedle system other than the lipophilic lidocaine molecule. Furthermore, we 
applied spray coating in the patch fabrication. The spray coating process is cost-effective 
and a variety of drug molecules are expected to be adapted in the adhesive-free patch 
system. The resulted lidocaine HCl dry patch plus microneedle pretreatment system can 
achieve similar effectiveness as the commercial lidocaine patch yet with a faster onset of 





Chapter 7 Conclusions and future work 
7.1. Conclusions 
This thesis addresses the issues that influence the effective and safe use of microneedles as 
skin pretreatment for drug delivery. These findings are very important for a reasonable 
design of a microneedle system and the correct use of microneedles for effective skin 
permeation enhancement. Meanwhile, antimicrobial microneedles were proposed to reduce 
the risk of infection associated with microneedle usage. Some of the findings are patented. 
Brief conclusions from the studies were summarized below. 
When studying the delivery efficacy of microneedle assisted transdermal drug delivery, it 
was observed that microneedle application force can influence the performance of skin 
permeation of copper peptide by affecting the depth and percentage of microneedle 
penetration through skin. The skin permeation of copper peptide can be enhanced by 
microneedle pretreatment at a high thumb force with minimal skin disturbance. Regarding 
the safety of the delivery, it was found that copper peptide has a low potential of inducing 
skin irritation response when compared to copper chloride and copper acetate. Besides, 
human epidermis and rat skin may not be suitable models for in vitro skin permeation study 
when microneedles are used. It further confirmed that enhanced delivery of copper peptide 
by microneedles is safe to skin. Besides, IL-1α, IL-8, FOSL1, and HSPA1A are potential 
in vitro biomarkers that can be used in adjunct to MTT assay in identifying irritants and 
assessing the skin irritation potential of copper compounds. 
On the other hand, a series of novel QAS copolymers with improved biocompatibility was 
synthesized and they can form effective and durable coatings via a thermal-curing process. 
The new QAS copolymers have a great potential to be used as a safer substitute for the 




infection associated with microneedle use, microneedles with durable and effective 
antimicrobial properties were developed by coating with a QAS copolymer after 
plasma treatment and good biocompatibility of the antimicrobial microneedles were 
demonstrated. 
Lastly, an adhesive and solvent free lidocaine HCl patch plus microneedle pretreatment 
system was fabricated and it can achieve similar effectiveness as the commercial lidocaine 
patch yet with a faster onset of 10 min, although 40 times less drug was loaded in the patch. 
7.2. Future work 
Following future work was proposed to further address the issues associated with the use 
of microneedle as permeation enhancer for percutaneous drug delivery. 
Another important factor critical to microneedle-assisted drug delivery is the lifetime of 
the micro-sized channels created in the skin. On one hand, rapid closure of the 
microchannels when the patch is applied on the skin, may result in sub-therapeutic levels 
in the body. On the other hand, if the microchannels remain open even after removal of the 
patch, it may result in problems such as irritation, infection and contamination of the site 
(251). Therefore, it is important to understand formation and closure of microchannels 
following microporation. Several groups reported their study on pore closure and provided 
important insights regarding the study of microchannel lifetime (31, 84, 252) . However, 
there are still limited studies available on the mechanisms of restoring skin barrier function 
following microneedle treatment. More future studies should be carried out. 
Further optimization has to be done for lidocaine HCl dry patch system. Besides, we can 
include a peripheral layer of adhesive for skin adhesion, and integrate the patch with a 




Other coating methods other than flood coating can be developed for antimicrobial coating. 
The QAS copolymer can also be used to coat other microneedle product, such as 










Chapter 8 Appendix 
8.1. Appendix to Chapter 4 
8.1.1. FE-SEM analysis 
FE-SEM was applied to analyze the antimicrobial mechanism of QAS copolymer by 
investigating bacteria morphology change. S. aureus was adjusted to a concentration of 109 
cells/ml before incubating with or without PMT-10% (to a final concentration of 2×MIC) 
for 0.5 h, and the obtained solutions were centrifuged at 4000 rpm for 5 min. The 
precipitated bacteria were rinsed twice with PBS, immobilized with 2.5% glutaraldehyde 
for 60 min, and again rinsed with water twice. Cell dehydration was performed using a 
series of ethanol/water solutions (35, 50, 70, 90, 95, and 100%), and the final dehydrated 
sample was transferred onto carbon tape and dried at room temperature for 2 days. Platinum 
sputtering was applied to coat the dry samples before FE-SEM (JSM-6700F, JEOL, Japan). 
As mentioned earlier, the QAS copolymers are able to disrupt the cytoplasmic membrane 
of bacteria via the interaction between the cationic quaternary ammonium group of the 
polymers and the anionic bacterial cell surfaces. This membranelytic mechanism was 
further investigated by using SEM to characterize the morphology change of S. aureus cells 
after incubation with the QAS copolymer. Since there were not much solid residues that 
could be found after mixing polymer with bacteria at the same concentration (105 cells/ml) 
with the MIC test, a higher bacteria concentration (109 cells/ml) was used for SEM testing. 
As another evidence to show the efficiency of QAS copolymers, the cloudy bacterial 
solution became semi-transparent after the incorporation of PMT-10%, and a significant 
reduction in the amounts of bacterial residue pellets were observed after the centrifugation. 




Reference source not found.A and B respectively. It can be found that survival S. aureus 
treated with an above MIC concentration of PMT-10% had obvious membrane blebbing 
and was covered by the mixture of QAS copolymer and sticky intracellular constituents. 
 
Appendix 1 SEM images of S. aureus before (A) and after (B) 30 min treatment with PMT 
-10% at 2 ×MIC. 
8.2. Appendix to Chapter 6 
8.2.1. Surface characterization by atomic force microscopy (AFM) 
In order to evaluate the coating evenness after coating, the topography of the backing films 
with or without lidocaine HCl coating was examined by easyScan 2 FlexAFM (NanoSurf, 
Switzerland) in noncontact mode. The AFM imaging showed that the backing layer are 
very smooth both before and after the drug coating, which indicated the drug is evenly 





Appendix 2 AFM imaging. (A) Backing film with surface roughness of 5.3 nm. (B) 
Lidocaine HCl dry patch with surface roughness of 1.3 nm. 
8.2.2. Thermal analysis by differential scanning calorimetry (DSC) 
DSC analysis of drugs and the respective dry patch were performed using a differential 
scanning calorimeter DSC Q200 V24.4 Build 116 Model (TA Instruments, Water LLC). 
Around 5 mg of drug powder or dry patch (liner removed) was sealed in aluminum pans 
and heated from 20 to 250 °C with a heating rate of 20 °C/min under a nitrogen gas flow 
rate of 30 ml/min. The results were analyzed using TA Universal Analysis 2000 V4.5A 





Appendix 3 Thermal analysis by DSC. (A) Lidocaine HCl and dry patch (liner removed). 
(B) Lidocaine and dry patch (liner removed). 
The DSC thermograms of lidocaine and lidocaine HCl monohydrate powder showed that 
there was a sharp endothermic peak at around 69.9 and 83.7 °C due to the crystalline form 
of lidocaine and lidocaine hydrochloride. For lidocaine HCl dry patch, no melting 
endothermic peak was observed, which suggests that lidocaine HCl may exist as 
amorphous state on the dry patch. However, for lidocaine dry patch, the small endothermic 




Furthermore, no crystalline structure was observed on lidocaine HCl dry patch by AFM as 
well (Appendix 2).  
8.3. The formulation effect of oligodeoxynucleotides (ODNs) on microneedle-assisted 
drug delivery 
Direct cell-cell communication through connexin 43 (Cx43) gap junction channels played 
an important role in the wound healing process. Downregulation of Cx43 expression at 
skin wound sites can dramatically improve the rate and quality of healing, which was 
associated with a reduced inflammatory response, enhanced keratinocyte proliferation and 
wound fibroblast migration (253). The treatment with Cx43 antisense 
oligodeoxynucleotides (ODNs) was shown to downregulate the Cx43 protein levels in the 
early stage of skin healing process and result in a dramatic increase in the wound closure 
rate (254). Although the Cx43 antisense gel is effective for the healing of many open wound, 
it is not effective for pressure ulcers, where the skin is intact, because the ODNs with a 
molecular weight of 9308 Da have difficulty in conquering the stratum corneum barrier. 
Here we proposed the use of microneedles to facilitate the delivery of the antisense ODN 
drug into the skin.  The effect of formulation type and drug concentration was evaluated. 
Since the microneedles were used as pretreatment, the micro-sized pores may close with 
time, which can influence the possibility of sustained drug delivery. In this study, a 
preliminary in vivo test was conducted to study the pore closure time as well. The work is 
still ongoing. 
8.3.1. Concentration and formulation effect on drug delivery 
Human dermatomed cadaver skin was defrosted and hydrated in tap water for around 30 
min. The skin was then spread over a PDMS substrate mounted on a Styrofoam board with 




MSS) were applied on the skin with a hand force of around 20 N for 10 s. 10 µl of different 
concentrations (1 µM, 5 µM, 10 µM) of Fluorescence labelled Cx43 antisense ODNs either 
in water or in 30% Pluronic F127 gel was applied on the microneedle treated area 
immediately. After 2 hours, the excess DNA sample on skin surface was wiped off with 
wetted Kimwipes for 3 times. Then the skin was fixed in 10% Neutral Buffered Formalin 
(Sigma-Aldrich, US) in the fridge for 2 days. After that, the skin was imaged by using a 
fluorescent Stereoscopic Nikon SMZ1500 microscope (Melville, NY) to have a top view 





Appendix 4 The surface images of human cadaver skin with different formulations of 
fluorescence-labeled antisense ODNs after MN treatment. 
In Appendix 4, clear patterned fluorescence dots retained on skin surface indicated that 
ODN drug penetrated the human skin through passages created by microneedles. For both 
solution and gel formulations, the higher the drug concentration, the more and brighter 
fluorescence dots were observed. The intensity of the fluorescence on ODN solution treated 
human skin are stronger than that on gel treated human skin at the same drug concentration. . 




the drug has to transport from the gel sample to the skin surface first before it can be 
absorbed by the skin through the micro-sized passages. 
8.3.2. Observation of drug penetration into skin after microneedle treatment 
After human dermatomed skin was treated by 3M MSS with a hand force of around 20 N 
for 10 s, 20 µl of Fluorescence labelled Cx43 antisense ODNs either in water or in 30% 
Pluronic F127 was applied on the microneedle treated area immediately. After 2 hours, the 
excess DNA sample on skin surface was wiped off with wetted Kimwipes for 3 times. Then 
the skin was fixed in 10% Neutral Buffered Formalin (Sigma-Aldrich, US) in the fridge 
for 2 days, followed by sucrose equilibration overnight in fridge to protect skin samples 
from ice forming in the embedding step. Then the skin samples were embedding in OCT 
medium and cut in 14 µm thick sections from the stratum corneum side to the dermis side. 
The thin section was transferred to a glass slide and rehydrated in PBS for 10 min. After 
the skin section was tapped dry by tissue paper, a drop of DAPI solution was put on the 
skin section for 10 min. Then the DAPI solution was washed off and a drop of glycerol 
was put on the skin section followed by covered with a coverslip. The coverslip was then 
sealed with nail polishing liquid. The processed skin sectioning samples were then imaged 





Appendix 5 Skin penetration of fluorescence-labeled antisense ODNs. (A) and (B) are the 
histological section of human skin stained with DAPI by applying with fluorescence-
labeled antisense ODN solution sample and gel sample, respectively. 
From Appendix 5, it was observed that the fluorescent antisense ODNs passed through the 
sites of stratum corneum perforation and go deep into the dermis layer of the skin. The 
solution sample can diffuse deeper into the skin than the gel sample. It indicated that we 
should control the gel viscosity to optimize the drug delivery into skin. 
8.3.3. In vivo percutaneous delivery of antisense ODNs on the mouse skin. 
Mice were anaesthetized with isoflurane gas. Then hair on the back was shaved to 
minimum 4 cm (H) × 3 cm (W) followed by hair removal cream (NairTM) application and 
removal after 1 min. The skin was further sterilized by 70% ethanol wipe for 3 times. Then 
the 3M MSS was pressed on skin for 10 s and 1 µM antisense ODNs in 15% Pluronic F127 
gel was spread on the microneedle treated area. After 10 min to allow antisense ODNs to 
be absorbed into skin, TegadermTM film was carefully covered around the gel. Then the 
mouse was put back into cage with water and food feeding. After 4 hours, the mouse was 
sacrificed and the treated skin was cut and put into embedding solution. The skin samples 
was then imaged by using a fluorescent microscope to have a top view of the microneedle 





Appendix 6 The image of mouse skin at 4 h after MN pretreatment plus antisense ODN 
gel treatment. 
From Appendix 6, it was observed that the passages created by microneedles were still 
visible at 4 h after microneedle pretreatment. However, no green fluorescence was found 
deep into skin during the histological section observation. It may because the concentration 
of antisense ODNs used in the gel is too low, or because of the fast degradation of antisense 
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